# Onsite

# **Siemens Healthineers**

BN™ II System Onsite Training Workbook



© 2023 Siemens Healthineers Inc. All rights reserved.

This manual, and the software described in this manual, are copyrighted. No part of this may be copied, reproduced, translated or reduced to any electronic medium or machine-readable form without the prior written consent of Siemens Healthineers Inc.

BN is a trademark of Siemens Healthineers Inc.

All other products mentioned are trademarks are the property of their respective owners.

### Table of Contents

- 1: Welcome
- 2: System Startup Daily Maintenance
- 3: Product Inventory Lot Data Entry
- 4: Assay Calibration
- 5: Process Controls
- 6: Process Barcoded Samples
- 7: Assay Calibration (Non-Kit & Kit)
- 8: Process Non-Barcoded Samples
- 9: Adding Tests and Changing Dilutions
- 10: Batch Programming (optional)
- 11: BNII Shutdown and Data Folder Backup
- 12: Maintenance
- 13: Process Barcoded Samples
- 14: Patient Demographics (optional)
- 15: Defining Other Vendor's QC
- 16: Process Short Samples
- 17: Troubleshooting
- 18: Resources

# 1 Welcome

### Welcome to Training

Siemens Healthineers would like to welcome you to the onsite training on the  $\mathsf{BN}^{\mathsf{M}}$  II System.

This course is designed to teach you the skills needed to operate, calibrate, maintain, and troubleshoot the BN<sup>™</sup> II System. Our staff welcomes the opportunity to present this training program to you.

### **Operator Training Course Goals**

The goal of this course is to prepare the customer to operate, maintain, and train others on the  $BN^{m}$  II System.

### **Course Objectives**

- Identify system components
- Navigate the system software
- Enter Lot Data
- Process calibration and controls
- Evaluate calibrations, controls, and sample results
- Process patient samples including barcoded and non-barcoded
- Edit patient sample requests
- Perform maintenance procedures
- Perform Shutdown and Data Folder Back up
- Perform basic system troubleshooting

# Training Agenda

Morning	Afternoon
Day 1	Day 1
Introduction/Training Expectations	Review calibration and control results
PACE microsoft form	Log Book Overview
Online Refresher Questions	Process Non-barcoded samples
Review Agenda	Add Test Requests and Dilutions
System Components Overview	Discuss:
System Startup – Daily Maintenance	QC Statistics
System Software Overview	External Predilution
Product Inventory	Non-specific reaction
Scan in Lot Data	Batch Programming (optional)
Manual entry Lot Data	Perform BNII Shutdown
Process Calibration (no supplemental reagent)	Data Folder Backup
Load Reagents	
Load Protein Standard	Note: Prepare the neodisher GK for maintenance
Process Controls	on day 2.
Load Controls	
Review calibration and control results	
Review calibration curve	
Review calibration flags and options	
Review QC results	
Review QC flags and options	
Process Barcoded Samples	
Discuss manual predilution	
Review Lab Journal options	
Review results and flags	
Process Calibration (supplemental reagent)	
Manual Reagent ID	

### Training Agenda

Day 2	
Eye Opener Questions	
System Startup – Daily Maintenance	
Perform Maintenance	
Weekly	
Monthly	
Half-Yearly	
Discuss Yearly	
Process Barcoded Samples – STAT	
Definitions Overview	
Patient Demographics (optional)	
Process Short Samples	
Define Other Vendor's QC (optional)	
Perform Troubleshooting	
Perform BNII Shutdown	
Data Folder Backup	
Finale Questions	
Validation Checklist Microsoft Form	
Customer Course Evaluation Microsoft Form	

### BN™ II System Onsite Training Course Validation Checklist

The participant places a checkmark beside the competency when it is completed. When all competencies are checked, the instructor and participant will sign and date below as a record of completion.

Topics	Competencies	Completed
System Components and	Identify the system hardware components	
Software Overview	Navigate System Software	
Product Inventory	Perform Lot Data Entry	
	Perform Manual Lot Data Entry	
System Startup - Daily Maintenance	Perform the tasks listed in the Quick Reference Guide - System Startup	
	Request calibration and controls - Load standards, controls, and reagents	
Calibration and Controls - classical & latex	Review calibration curve	
	Review calibration flags and options	
	Review QC results	
	Review QC flags and options	
	Describe QC Statistics	
Samples	Process barcoded samples - manually enter requests	
	Process non-barcoded samples	
	Evaluate sample results	
	Add test requests: repeat measurement, repeat measurement from another dilution, change a dilution, STAT	
	Process a low-volume sample	
	Describe External (manual) Predilution	
	Describe a non-specific reaction	

Definition Overview	Define other vendors' controls	
	Define profiles	
Log Book	Respond to an error	
	Describe Log Book options	
Configuration Overview	Describe options and functions	
Maintenance	Perform Weekly maintenance	
	Perform Monthly maintenance	
	Perform Half-yearly maintenance	
	Discuss Yearly maintenance	
BN II Shutdown	Perform a shutdown	
Data Folder Backup	Perform Data Folder Backup	
Troubleshooting	Manually identify an unreadable barcode	
	Respond to and correct programmed samples	

Instructor: Participant: Date:

What was most helpful to you during this program?

How can we improve this program to make it more meaningful to you?

2 System Startup – Daily Maintenance

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

#### Objectives

- Perform Daily Maintenance tasks
- Startup the System
- Update the Dilution Well count

- 1. Check System Liquids, Waste, and Dilution Strips
  - Replenish the buffer, diluent, and wash solution (1 bottle of BN II Additive to 5 L of distilled water) as needed.
  - Empty the waste if necessary.
  - Replace used dilution strips and carefully place the dilution frames into position.

Note: The system will not initialize if the dilution frames are not placed correctly in the dilution frame holder.

After preparation, how long is the Wash Solution good for?

What is the expiration date for the diluent and buffer when in use?

Does the system notify you if the waste is full?

- 2. Initialize the System
  - Turn on the BN II analyzer using the button on the left side.
  - Turn on the computer.
  - Log in to the Operating System.
  - When the desktop appears, double click on the BNII Alias icon.
  - In to the BNII software, enter User & Password in the Login/Logout box.
  - In the Info dialog observe the Information display area beneath System status.
  - During initialization, do not interrupt the movements by performing any hardware function, such as lifting the front panel or loading a rack.
  - Check the tubing and syringes for kinks, leaks, air bubbles and dirt.

If there are air bubbles or dirt, rinse tubing and syringes several times by selecting System - User Service- Syringe. Select the syringe, washing solution, the number of washing steps and Rinse.

Note: The Information Display Area will show "analyzer is ready" in the system status field after the completion of initialization.

What are the sizes (uL) of the three syringes?

- 3. Update the Dilution Well Count
  - When the Dilution strips dialog appears, click Change dilution strips.
  - You have already changed the strips, so click Left new, then Right new and OK.
  - The value for Diln wells in the Analyzer display area should be 264.

How many cuvettes are available to use?

How many cuvettes are on the system?

```
3 Product Inventory – Lot Data Entry
```

- BN<sup>™</sup>II System Instruction Manual
- BN™II System Quick Reference Guide

#### Objectives

- Identify Siemens lot numbers for reagents, standards, and controls.
- Enter lot data using the barcode scanner.
- View lot data for standards and controls.
- Manual entry of lot data

- 1. Observe the lot number on the box or bottle for reagents, standards, and controls. The last 2 digits is the lot number sometimes followed with a letter and the first 4 digits is the product identifier.
- 2. Following the procedure in the QRG, scan the assigned values of standards and controls.
- 3. To view the assigned values, click Calibration > Control lots or Standard lots.

When would an assigned value need to be entered manually?

 What size bottle are reagents packaged in?

 What size bottle are standards and controls packaged in?

4. Using the QRG, manually enter in values for a control or standard that has not been scanned in.

Why would a control or standard require manual entry of values?

4 Assay Calibration

- BN<sup>™</sup>II System Instruction Manual
- BN™II System Quick Reference Guide

#### Objectives

- Load reagents
- Program calibration for assays with no supplemental reagent
- Respond to instrument needs.
- Review calibration curves.

- 1. Load Reagents (assays with no supplemental reagent)
  - Place bottles in a reagent rack with the barcode labels positioned to face the barcode reader.
  - Push the rack into any of the lanes 1 through 5 until you hear a click.
  - Do not load the standard.
- 2. Program Calibrations
  - Click on the Reference curves icon.
  - Click on the assay. Be sure the BNII icon is displayed next to the reagent lot onboard the system.
  - Click Measure. The color of assay changes from green to blue, indicating that the calibration is in progress.
  - Click Yes to the message if the lot has already been calibrated.
  - Repeat the previous steps for additional assays with no supplemental.
  - Close the Reference curves window.
- 3. Determine Instrument Needs
  - Note the red background on the Info dialog.
  - Click Missing in the Reagents display area.
  - Standard is listed in red because it is needed.
  - Load the Standard in a control rack. Make sure the barcode label faces the rack opening. Place the rack in any lane, 6 through 15, and listen for the click.
  - Close the window and look at the Validation display area. Note the number in the in process field. This indicates the number of calibration curves are in progress.
  - Observe the movement of the right and left transfer arms.
- 4. Review Calibration Curves
  - When the curves are completed, click on the Reference curves icon.
  - Highlight an assay and verify that the correct lot number is displayed.
  - Click Show curves.
  - Determine curve validity. Acceptable mean deviation for most assays is  $\leq$  5.0%.

Note: Most assays can have 3 reagent lot numbers calibrated and 3 curves per lot.

How many reagent bottles can be placed in a rack? \_\_\_\_\_\_ Does the system show a time when the assays are completed? \_\_\_\_\_\_ Which transfer arm probe goes into the reagent bottle? \_\_\_\_\_\_ Why is it important to review the calibration curve if it has been automatically accepted?

# 5 Process Controls

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

### Objectives

- Request controls.
- Determine instrument need.
- Review control results.

- 1. Request Controls
  - Display the Routine menu and select Request controls.
  - Highlight the Xs for the assays that are calibrating.
  - Click Measure. The Xs change to ?s, indicating that the controls are in process.
  - Close the window.
- 2. Determine Instrument Needs
  - Click Missing in the Reagents display area.
  - Refer to the displayed list to load the controls that are needed.
  - Close the Reagent list.
- 3. Review Control Results
  - When results are available, click the Control journal icon.
  - Review the icons in the tool bar.
  - The Control journal displays:
    - o Percent deviation from the mean value of the control
    - o Results in concentration
    - o Expected mean in parentheses
  - For most assays, the controls are acceptable if they are ±15% from the mean value.

How does the system know the mean value of the controls?

How many control bottles can be loaded in one rack?

Why are the bottles tilted in the rack?

If the control result is outside of the  $\pm 15\%$  acceptability, will the system allow samples to be processed?

6 Process Barcoded Samples (no interface)

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

#### Objectives

- Enter requests for barcoded sample (no interface).
- Determine instrument needs.
- Load sample racks in appropriate lanes.
- Review sample results.

- 1. Processing barcoded samples with no interface
  - Follow the procedure in the BN II Quick Reference Guide.
  - Assign tests

Which transfer arm probe goes into the sample tube?

How many samples can be loaded in one rack?

How many samples can be loaded on the system at one time?

- 2. Review Results
  - Click on the Lab journal icon to view the sample results.
  - When all sample results are available, click on the printer icon in the upper left corner of the window to print the results.

In the Lab Journal, click on the light bulb. $\widehat{}                $	
Describe the Turbidity Flag	

What needs to be done with a sample that has a turbidity flag?

Note: See IFU Limitations of the Procedure (Resources - Training Workbook)

# 7 Assay Calibration (non-kit & kit)

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

#### Objectives

- Enter new reagent lot number automatically.
- Manual identification of a reagent.
- Calibrate non-kit and kit assays.
- Review calibration curves.
- Process and review quality control.

- 1. Load Reagents (kit)
  - Load a rack with reagent and its supplemental reagent and insert in any lane 3, 4, or 5.
    - Click Reagents in the Reagents display area on the Info dialog. Note that supplemental reagent is marked with a black X in the Lane 3-5 column. This means the reagent must be placed in lanes 3, 4, or 5 so the right transfer arm can reach it.
  - The new lot numbers are entered automatically, and you will see the message New lot number of reagent is on board the analyzer. Please measure a new calibration curve (lot number). Click OK and the Reference curves dialog opens automatically.
  - Click Yes to the message if the lot has already been calibrated.
  - In the Reference curves dialog, select the assay. Because the reagent and supplemental are from the same box (kit), the lot numbers will be displayed on the right and the BNII icon will be seen next to the lot numbers. If not, click on the triangle and choose the lot number. The reagent and supplemental are from the same kit and should always be used as a pair.
  - Click Measure.
  - Click Missing in the Reagents display area.
  - Standard is listed in red because it is needed.
  - Load the standard in a control rack. Place the rack in any lane, 6 through 15, and listen for the click.
- 2. Load Reagents (non-kit)
  - Load a rack with reagent and its supplemental reagent. The supplemental reagent is packaged separately (non-kit). Intentionally turn the supplemental reagent barcode label so the scanner cannot read it.
  - Load the rack. The rack is ejected automatically, and the Loading dialog appears. This happens because the barcode scanner cannot read the label for the supplemental reagent.
- 2. Manual Reagent Identification
  - Check the lot number on the supplemental reagent vial in the rack.
  - Click on the reagent rack position marked with a "?"
  - Scroll down the list on the right and highlight the supplemental reagent with the correct lot number beside it. Click Take at the lower right corner of the dialog.
    - Note if you do not see the correct lot number, in the menu, select Calibration > Reagent lots. Select the reagent and enter the new lot no.
  - When the message All vials/bottles have been identified appears, click OK.
  - Pull the rack halfway out of the lane and reinsert it.

- 3. Program Calibrations
  - Click on the Reference curves icon.
  - Click on the assay. Be sure the BNII icon is displayed next to the reagent

lot onboard the system. The supplemental reagent will not be displayed because it is packaged separately from the reagent and has a different lot number (non-kit).

- Click Measure. The color of assay changes from green to blue, indicating the calibration is in progress.
- Click Yes to the message if the lot has already been calibrated.
- Close the Reference curves window.
- 4. Process Controls
  - Display the Routine menu and select Request Controls.
  - Highlight the Xs for the controls.
  - Click Measure.
  - Close the Control Request window.
- 5. Review Calibration Curves
  - Click on the Reference curves icon.
  - Click the assay then Show curves. Click on the printer icon to print the curve (optional).
  - Evaluate the curve(s) acceptability.
- 6. Determine Control Acceptability
  - For most assays, the controls are acceptable if they are ± 15% from the mean value.

Note: Kit assays can have 1 lot number calibrated and 3 curves per lot.

When will a reagent lot need to be manually entered?

What is the purpose of the supplemental reagent?

Can a control be ordered if there is no acceptable calibration curve?

# 8 Process Non-Barcoded Samples

- BN<sup>™</sup>II System Instruction Manual
- BN™II System Quick Reference Guide

#### Objectives

- Manually build a job list.
- Assign rack positions for non-barcoded samples using Autoload.

- 1. Processing non-barcoded samples
  - Follow the procedure in the BN II System Quick Reference Guide.
- 2. Lab journal Review
  - Review results.

On the toolbar in the Lab journal, what is clicked to display the description of the flags?

What icon in the Lab journal indicates a sample has been processed?

9 Adding Tests and Changing Dilutions

- BN<sup>™</sup>II System Instruction Manual
- BN™II System Quick Reference Guide

## Objectives

- Add tests to previously processed samples.
- Repeat assays and change dilution factors.
- Change the dilution factor for an assay before the sample is processed.

- 1. Add a test to a sample
  - Select the Lab journal icon.
  - Double-click the sample ID. The dialog Enter job list is displayed. In the Assays field, click the assay to add.
  - To add an assay for multiple samples, select the samples in the Lab journal. Then, in the toolbar, click ? and add the assay to the selected samples
  - To save the changes, click Save or Save & Close.
- 2. Repeat Assays and Change the Dilution Factor
  - In the Lab journal click on the assay result.
  - Click Action and select Repeat. The dialog Dilutions is displayed.
  - Click on a dilution.
  - Click Measure.
- 3. Change the Sample Dilution Factor before Processing
  - Use the Enter job list function to program a new sample.
  - Click on the Dilution button.
  - Click on a dilution field to highlight it.
  - Click on the New dilution (pencil/tablet) icon in the toolbar. The X will move to the field that is highlighted.
  - Click OK.
  - Click Save.
  - Load the sample.

Why would the dilution factor be changed on a sample prior to processing?

# 10 Batch Programming (Optional)

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

# Objectives

- Program a batch run.
- Delete the programming.

- 1. Programming
  - Select Routine, Enter job list.
  - Click on the Batch Input box.
  - Enter Number of samples 10.
  - Enter the Start Number 125.
  - You may put a precursor name or number in the Sample ID field, eg, Health Fair.
  - Click on the assay(s).
  - Click Save and Close.
  - Open the Lab journal to view the sample IDs and requests.
- 2. Deleting
  - In the Info dialog click Missing in the Samples display area.
  - Click Edit, Select all to highlight the samples.
  - Click on the Delete icon and choose Complete Selection.

What is an advantage of batching samples for processing?

# 11 BNII Shutdown and Data Folder Backup

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

# Objectives

- Shut down the analyzer
- Delete the Runtime Folder
- Back up the Data Folder

Note: The Data Folder stores important information relating to calibrations, assays, standards, and controls. A backup copy of the Data Folder can be used to restore this information on your system.

Each time the BNII program is launched, it automatically makes a copy of the Data Folder. The system stores a total of 4 copies. When the analyzer initializes, if you see no assays listed or valid reference curves stored, the Data Folder could be empty or corrupted. Each time the BNII program is launched, it will make a copy of the empty or corrupted Data Folder. It is recommended that you call the Siemens Healthineers Technical Solutions Center immediately to assist you with restoring the Data Folder.

Additionally, you should backup the Data Folder to a USB when new calibrations have been run, new information has been entered for assays, standards, and control, and for Weekly Maintenance.

- 1. Shut Down the BNII Application
  - Print the Lab journal: Lab journal icon, Printer icon.
  - Release results if interfaced: Lab journal icon, Release to Host icon.
  - Delete the Lab journal:
    - o Click the Lab journal icon.
    - o Click the Edit menu and choose Select All to highlight the results.
    - o Click the Trash Can icon.
    - o Click Complete Selection.
    - o Close the Lab journal window.
  - From the menu bar select BNII and select Quit BNII.
  - Click Perform.
  - Click Close.
  - DO NOT click Cancel prematurely. Wait until the desktop appears.
- 2. Using the BNII Quick Reference Guide perform the Data Folder Backup
  - Delete the Runtime folder.
  - Copy Data Folder to the USB.
  - Empty Trash.
  - Shutdown BNII and turn off.

# 12 Maintenance

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

# Objectives

- Perform weekly maintenance
- Perform monthly maintenance
- Perform half-yearly maintenance
- Discuss yearly maintenance

#### 12.1 Weekly Maintenance

- 1. Clean the Surface of the system
  - Clean the surface of the system with a link-free cloth moistened with cleaning solution (rotor cover, the trough for the dilution frames and the rack unit).

NOTE: Do not use alcohol to clean the Plexiglas.

- 2. Check the syringes and valves for leaks
  - Check the syringes and valves for leaks.
  - Check for crystallization of buffer at the transition from syringe to valve.
  - If valves are leaking contact a service representative.

When do you check the tubing and syringes for kinks, leaks, air bubbles, leaking and microbial contamination?

- 3. Check the reagent and sample probes for damage and blockage
  - Select System > User service > Clean dispensing probe.
  - Select Yes.
  - Select Clean now.
  - Lift the Plexiglas and clean the tip of both probes with a lint free cloth moistened with cleaning solution.
  - Select Cleaning done

NOTE: The sample transfer arm and then the reagent transfer arm will move one after the other to an adjustment point in lane 15. (approximately 20 second intervals)

- Check the probe is directly above the notch on lane 15. If it does not align contact Siemens Healthineers service.
- While the reagent transfer arm moves to the adjustment point, the sample probe moves to the washing station. The probe moves over the washing station and dispenses liquid.
  - Evaluate the liquid must dip straight into the washing station and be cylindrical and transparent. It must not be fanned and must not splash.
- Then the reagent transfer arm moves over the left washing station and dispenses liquid.
- Select Done.

What needs to be done if the liquid dispensed does not meet the criteria mentioned above?

How do you clear a clogged sample dispensing probe?

- 12.2 Monthly Maintenance
  - 1. Replace the washing solution container
    - Replace the washing solution container with a used and clean diluent container. This helps to prevent contamination buildup.
  - 2. Purge the tubing and waste container (recommended)
    - Prepare the neodisher GK the DAY BEFORE this procedure, if undissolved it can obstruct the tubing.
      - Fill a container with 4L of distilled water. For each L add 10g of the neodisher GK (approx. 1 cap full).
    - Fill another container with 1L of the prepared purging solution.
    - Empty the external waste container.
    - Select System > User service > Purging.
    - Select OK.
    - Select check box Include purging of the waste container.
    - Time to take effect: 30.

Purging				
Include purging of the waste container The purging of the tube system takes at least 30 minutes depending on the defined setting and time to take effect.				
Time to take effect 30				
Click Start to perform the automatic purging process.				
Start Cancel				


- Select Start.
  - The dialog states that the routine has been interrupted.
- Select Start.
- Place all three container level sensors into the 1L purging solution container.
- Select Continue.

Note: Completed steps are marked with a green check mark under the icons.

• When the dialog box below appears, place the drain tube of the external waste into the remaining 3L purging solution.



- Select Continue.
- When the dialog box below appears, take the drain tubing out of the purging solution and place it back into the external waste container.



- Take all the intake nozzles out of the purging solution, rinse with distilled water, clean with a damp lint-free cloth and place back into the appropriate containers.
- To start the rinsing process, select Continue.
- When all purging solution has been rinsed out of the system, the dialog states Analyzer in Routinemode. To confirm this message, select Continue.
- Select Quit when the dialog states Purging of the tubing is finished.
- The dialog is closed.
- 3. Replace the wash solution filter
  - On the left side of the system, loosen the Luer lock connections of the old washing solution filter.
  - Insert the new filter. Close the Luer lock connections.

NOTE: Wash filter is changed before replacing cuvettes to avoid getting residual neodisher into the cuvettes.

- 4. Replace cuvettes
  - In the software select System > User service > Cuvette.
  - Select Yes when the dialog is displayed.
  - The dialog Cuvette is displayed.


Max. blank value: 500	Blank Value	No. of cuvette	Blank Value	No. of cuvette	Blank Value	No. of cuvette
	136	41	143	21	152	1
Accept new threshold	122	42	133	22	141	2
	304	43	319	23	144	Э
	175	44	230	24	154	4
	160	45	212	25	141	5
	160	46	234	26	149	6
Number of cuvettes	136	47	181	27	240	7
above the blank value: 4	243	48	132	28	343	8
	131	49	624	29	524	9
Mean value: 193	1109	50	132	30	242	10
	129	51	298	31	271	11
	127	52	203	32	336	12
	132	53	158	33	214	13
	133	54	144	34	493	14
	133	55	150	35	419	15
Measure cuvette blanks	233	56	185	36	175	16
	221	57	189	37	218	17
Replace cuvettes	505	58	178	38	150	18
	215	59	150	39	129	19
Cancel OK	136	60	138	40	206	20

- Select Replace cuvettes shown in the dialog box above.
  - The right transfer arm is moved to another position so the rotor cover can be removed.
- The dialog below is displayed.

Open rotor lid and remove cuvette rotor.
Change cuvettes, insert rotor and then confirm.
Confirm

Do not select Confirm until after the cuvettes have been replaced.

- Lift the Plexiglas cover.
- Remove the rotor cover.
- Hold the rotor in position with hand while unscrewing the knurled nut with the other hand. Unscrew counterclockwise.
- Remove the rotor assembly by lifting up on the second knurled nut.
- Place the rotor assembly on the 3<sup>rd</sup> hand shown below.



- While holding the rotor assembly, remove the second knurled nut by unscrewing it counterclockwise.
- Carefully remove the top plate or upper part of the rotor assembly.
- Remove and discard the old segments.
- Load the new segments onto the rotor between the lines on the rotor plate.

NOTE: Handle the cuvette segments by the top tab only. Do not touch the cuvette body.

- Place the upper rotor plate onto the rotor plate where the cuvettes are seated. Make sure that the locator pin on the lower plate is seated in the hole on the upper plate.
- Hold the assembly and screw the second knurled nut back on tightly.
- Seat the assembly back into its original positioning. Spin the rotor until the locator pin in the rotor station fits through the hole in the rotor plate assembly.

NOTE: The top of the cuvettes should be even with the rotor station platform when seated properly.

- Hold the rotor assembly in place while screwing the knurled nut onto the assembly.
- In the dialog box, select Confirm.
  - o The analyzer drives the cuvette washing units back into position.
- Put the rotor cover back in position
- Close the Plexiglas.

NOTE: The instrument will automatically measure the cuvette blanks.

- 5. Clean the Mouse
  - Wipe the surface with a soft, lint-free cloth moistened with cleaning solution.

#### 12.3 Half-yearly Maintenance

Reference the BNII System Instruction Manual to perform the following:

- 1. Replace the syringes with the white piston heads.
- 2. Maintain the syringes with silicon oil.

#### 12.4 Yearly Maintenance

1. Replace the syringes with the black piston heads or contact Siemens Healthineers service to have them replaced.

13 Process Barcoded Samples (no interface)

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

# Objectives

- Process barcoded samples
- Program a STAT sample
- Filter results in the Lab journal
- •

- 1. Enter the Job list and Process the Samples
  - Load all sample rack(s). For this exercise, it is recommended that you put the samples in numerical order and load the rack(s) in order so that the sample numbers will be in numerical order in the Lab journal.
  - In the Samples display area on the Info dialog click without req.
  - Click Edit in the menu bar and Select all
  - Click the Details icon at the top of the window.
  - The first sample number read by the barcode scanner appears in the Sample ID box. Select the assay(s) and then click Save. Continue assigning assay(s) to sample numbers.
- 2. Program a STAT sample
  - Mark the last sample STAT.
  - In the Lab journal find the indicator for a STAT sample.
- 3. Filter Results in the Lab journal
  - When results are available:
    - o Click View in the tool bar and select Assay selection.
    - o Click an assay to see a list of all results.
  - To return to the default view, click on the Deselect filter icon (eyeball).

# 14 Patient Demographics (optional)

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

# Objectives

- Enter patient demographics
- Enter laboratory name and address
- Print single patient report

- 1. Enter Patient Demographics
  - Open the Lab journal and double-click on a processed barcoded sample to open the Enter job list dialog.
  - Click Patient and enter:
    - o Last Name: Doubtfire
    - o First Name: Irma
    - o Date of Birth: 12/29/1953
    - o Sex: Female
    - o Click Save.
  - Enter some patient information for two processed barcoded samples.
  - Click on the Patient Journal icon to view the entries.
- 2. Enter Laboratory Information
  - Select System, Configuration and Journal. Type in your laboratory's information.
  - Click Save.
- 3. Printing Patient Reports
  - Click on the Patient Journal icon and then click on the Print icon to print the entire Patient Journal.
  - To print a single patient report, highlight a patient name and click View and Own Selection.
  - Click on the Print icon.
  - To return to the normal display, click View and All Patients.

# 15 Defining Other Vendor's QC (Optional)

• BN™II System Instruction Manual

# Objectives

- Define controls
- Enter control lot numbers and nominal values
- Process control as a sample and change to a control

- 1. Define Controls
  - Select Definition, Controls.
  - Click on the New (pencil/tablet) icon.
  - Enter Name of control: Biorad 1.
  - Enter Identification: 9901. You must use a unique 4-digit identifier for each control.
  - Enter Expiration: 240 min.

What is the expiration used for?

- Leave bottle size default at 2 mL and click Save.
- If defining more controls, you can use 9902 as identification for Biorad 2 and 9903 as identification for Biorad 3.
- In the Control Definition dialog, highlight the cell at the intersection of the assay and the new control and click on the New assignment (pencil/tablet) icon to bring up the Control Details window. For this exercise, click IgG for Biorad 1.
- Enter 15% or 20% permitted deviation. When unassayed controls are used, 20% is recommended as the starting permitted deviation. You can change this later, if desired.
- Change the default dilution level, if necessary, to accommodate the analyte concentration in the control.
- Leave the other defaults for running controls unchanged and click Save.
- Close the Control Definitions window.
- 2. Enter Lot Numbers and Values
  - Select Calibration and Control Lots.
  - Double-click on the control name and enter the lot number of the control. You can use 01 for Biorad 1, 02 for Biorad 2, and 03 for Biorad 3.
  - Enter a nominal value for IgG for Biorad 1. Click Save.
  - To view the upper and lower limit based on a 20% deviation, double-click on the nominal value in the IgG cell for Biorad 1.
- 3. To Process Other Vendor's QC (Optional)
  - Pour control into a sample tube and either manually identify it using the 6digit number or print a barcode label for the control.
  - Change the sample to control. Select Action pop-up menu and Change sample to control...

Are the controls entered in the monthly QC statistics?

# 16 Processing Short Samples

- BN™II System Quick Reference Guide
- BN™II System Instruction Manual

# Objectives

- Customize System Configuration
- Process a sample in a pediatric rack

- 1. Customize System Configuration
  - Click System, Configuration, and Measurement. Verify that the box "Use same ID several times" is NOT marked. If this box is marked, the system will not allow samples to be assigned to a pediatric rack. However, if you are running 2 sample types with the same ID number (eg, CSF and urine from the same patient), this box must be marked. If you are changing this option, the Lab journal must be empty. Click Save.

Note: If the system is connected to a LAS, do not activate the check box Use sample ID several times.

- 2. Process a Sample with Insufficient Volume
  - Using the BN II System Quick Reference Guide for assistance, program assays on a non-barcoded insufficient sample.

Watch the transfer arm as it goes into the sample. What does the probe do?

What display area on the Info dialog changes to yellow?

- When you see the indicator for "insufficient sample" on the Info dialog, eject the rack.
- To delete the rack position for the sample, click on the Loading icon. Select the sample rack number in the Rack ID list. Highlight the sample ID and click Delete.
- To assign the sample to a pediatric rack, choose your pediatric rack and select that number in the Rack ID list. Click Autoload and Ignore all empty positions. Close the Loading dialog.
- Transfer the sample to a microcentrifuge tube and place in the pediatric rack. Load the rack on the BN II system.
- 3. Follow-up (optional)
  - When results are complete, delete the Lab journal.
  - Click System, Configuration, and Measurement. Mark the box "Use same ID several times" and click Save.

## 17 Troubleshooting

## References

- BN™II System Instruction Manual
- BN™II System Quick Reference Guide

## Objectives

Upon completion of this exercise, you will be able to:

- Troubleshoot basic hardware and software issues.
- Use Logbook messages to resolve issues

Your goal is to print your Lab journal with sample results. Your BN II has been programmed for samples to be run.

Before you insert the sample and reagent racks, resolve any issues in red noted on the Info dialog screen. Check the Logbook message for help. Record your observations and resolutions on the form below.

As samples are running, resolve errors and or issues that may appear.

Tip: Be sure to investigate the Logbook errors. Click on the error text and read in the Event and What to Do areas.

Problem:	
Resolution:	
Problem:	
Resolution:	
Problem:	
Resolution:	
Problem:	
Resolution:	

## 18 Resources



# **BN II System**

Assay Protocols

Update 4.6, Date of Issue: 2022-05

siemens-healthineers.com

	Version			Date	Changes
	Manual	Software	Assay Protocol Update		
	2.9	2.5/2.6	4.6	2019-09	Footnote 4: Cover Ring EVAP. STOPPERS added.
I	3.0	2.5, 2.6	4.6	2022-05	Reference Range: CRP
	Trademarks		CardioPhase is a trac All other trademarks		s Healthineers. of their respective owners.
	Software Copyri	ghts	All rights to this soft	ware are retained well as the printed	ne copyright property of Siemens Healthineers. by Siemens Healthineers. You are entitled to I documentation relating to it on one single,
	Disclaimer		software and custon and meet product sp Siemens Healthinee	nizable features fo becifications. User rs as they may affe nay vary from cou	e provided instructions, reagents, instrument, r this system to optimize product performance defined modifications are not supported by cct performance of the system and test results. ntry to country and is subject to varying

## **Table of Contents**

- Revision bar indicates update to previous version.
  - Changes are highlighted in blue, which may also include editorial corrections without content changes.

	Page
Applications in Use in the Laboratory	4
Table of Assay Protocols         Volumes and Dilutions	
Addendum I: Symbol Names of Required Materials, REF and SMN for all products	15

I

## Applications in Use in the Laboratory

🗵 yes	Abbr.	Assay Name	Page
	lgG	IgG / N Antiserum to Human IgG	7
	lgG1	IgG Subclass 1 / N AS IgG1	7
	lgG2	IgG Subclass 2 / N AS IgG2	7
	lgG3n	IgG Subclass 3 / N Latex IgG3	7
	lgG4n	IgG Subclass 4 / N Latex IgG4	7
	IgA	IgA / N Antiserum to Human IgA	7
	IgAs	IgA / N Antiserum to Human IgA	7
	IgM	IgM / N Antiserum to Human IgM	7
	lgMs	IgM / N Antiserum to Human IgM	7
	C3	C3c / N Antiserum to Human C3c	7
	C4	C4 / N Antiserum to Human C4	7
	TRF	Transferrin / N Antiserum to Human Transferrin	7
	ALB	Albumin / N Antiserum to Human Albumin	8
	AAT	$\alpha_1$ -Antitrypsin / N Antiserum to Human $\alpha_1$ -Antitrypsin	8
	a2M	$\alpha_2$ -Macroglobulin / N Antiserum to Human $\alpha_2$ Macroglobulin	8
	HPT	Haptoglobin / N Antiserum to Human Haptoglobin	8
	AAG	$\alpha_1$ -acid Glycoprotein / N Antiserum to Human $\alpha_1$ -acid Glycoprotein	8
	PRE	Prealbumin / N Antiserum to Human Prealbumin	8
	sTfR	soluble Transferrin Receptor / N Latex sTfR	8
	HPX	Hemopexin / N Antiserum to Human Hemopexin	8
	CER	Ceruloplasmin / N Antiserum to Human Ceruloplasmin	8
	RbP	Retinol-binding-Protein / N Antiserum to Human RbP	8
	kap	lg/L-chain, type kappa / N Antiserum to Human lg/L-chain, κ-type	8
	FLC_K	free lg/L-chain, type kappa / N Latex FLC kappa	8
	lam	Ig/L-chain, type lambda / N Antiserum to Human Ig/L-chain, $\lambda$ -type	8
	FLC_L	free Ig/L-chain, type lambda / N Latex FLC lambda	8
	A-I	Apolipoprotein A-I / N Antiserum to Human Apolipoprotein A-I	9
	АроВ	Apolipoprotein B / N Antiserum to Human Apolipoprotein B	9
	Lpa	Lipoprotein(a) / N Latex Lp(a) Reagent	9
	FRT	Ferritin / N Latex Ferritin	9
	RFn	RF / N Latex RF Kit	9
	ASLn	ASL / N Latex ASL	9
	CRP2	CRP sensitive / CardioPhase <sup>®</sup> hsCRP	9
	CRP1	CRP / CardioPhase® hsCRP	9
	lgE1	lgE / N Latex lgE mono	9
	ADNs	ADNase B / N Latex ADNase B	9
	b2M	$\beta_2$ -Microglobulin / N Latex $\beta_2$ -Microglobulin	9
	MYO	Myoglobin / N Latex Myoglobin	10
	CysC	Cystatin C / N Latex Cystatin C	10
	HCY	Homocysteine / N Latex HCY	10
	CDT	Carbohydrate-deficient Transferrin / N Latex CDT Kit	10
	C1I	C1-Inhibitor / N Antiserum to Human C1-Inhibitor	10
	FIB	Fibrinogen / N Antiserum to Human Fibrinogen	10
	AT3	Antithrombin III / N Antiserum to Human Antithrombin III	10
	PLS	Plasminogen / N Antiserum to Human Plasminogen	10
	lgGU	IgG / N Antiserum to Human IgG	10
	TRFU	Transferrin / N Antiserum to Human Transferrin	10

🗷 yes	Abbr.	Assay Name	Page
	ALBU	Albumin / N Antiserum to Human Albumin	10
	a1MU	α <sub>1</sub> -Microglobulin / N α <sub>1</sub> -Microglobulin Kit	10
	b2MU	$\beta_2$ -Microglobulin / N Latex $\beta_2$ -Microglobulin	11
	lgGC	IgG / N Antiserum to Human IgG	11
	IgAC	IgA / N Latex IgA	11
	lgMC	lgM / N Latex lgM	11
	ALBC	Albumin / N Antiserum to Human Albumin	11

**6**/17

## Table of Assay Protocols

SAN <sup>a</sup> A	bbr.	Protein	Specimen	Reagent Package	Quantity		On-board	Supplements	On-board	Recommended Controls	On-board Condition	Initial Measuring	Minimum Unit	Reference Range <sup>d</sup> Condition Unit	Standards	<b>APV</b> <sup>e</sup>	Eval. Mode
				Раскаде	Quantity		Stability <sup>b</sup> [days at 8 hours each]		Сп-воаго Stability <sup>b</sup> [days at 8 hours each]		Stability <sup>b</sup> [h]	Range	Minimum Unit Measuring Range	Condition Unit			
1 lg	IG	lgG	plasma;	N Antiserum to Hu NAS IGG	ıman lgG				-	N/T PROT CONTROL SL/L	n/a n/a	1.4 – 46	0.07 – 2.3 g/L	7.0 – 16.0º g/L	N PROT STANDARD SL	1.2	Fixed Time
			heparin plasma	<b>REF</b> OSAS19 SMN 10446299	1 ×	5 mL	5/10 <sup>f</sup>		_	N/T PROT CONTROL SL/H	n/a						
				<b>REF</b> OSAS11 SMN 10446297	1 ×	2 mL	3/6 <sup>f</sup>										
51 lg	IG1	lgG Subclass 1	serum; EDTA plasma; heparin	N AS IgG1 N AS IGG1					_	N/T PROT CONTROL SL/L	n/a n/a	0.85 – 27	0.04 – 1.4 g/L	4.05 – 10.11 <sup>g</sup> g/L	N PROT STANDARD SL	3.0	Fixed Time
			plasma	<b>REF</b> OQXI09 SMN 10446168	1 ×	1.5 mL	3/6 <sup>f</sup>			N/T PROT CONTROL SL/H	n/a						
52 lg	IG2	lgG Subclass 2	plasma; heparin	N AS IGG2				N SUPPLEMENT P	[	N/T PROT CONTROL SL/L	n/a n/a	0.35 – 11	0.09 – 2.8 g/L	1.69 – 7.86 <sup>g</sup> g/L	N PROT STANDARD SL	3.0	Fixed Time
78 la	G3n	lgG Subclass 3	plasma serum; EDTA	REF OQXK09 SMN 10446169 N Latex lgG3	1 ×	1.5 mL	3/6 <sup>f</sup>	N SUPPLEMENT P		N/T PROT CONTROL SL/H	n/a n/a	0.033 - 2.1	0.0017 – 0.11 g/L	0.11 – 0.85º g/L	N PROT STANDARD SL	1.0	Fixed Time with
78 ig			plasma; heparin plasma		1	2 ml nigg3 reagent		Cleaner SCS	5 [	N/T PROT CONTROL SL/M N/T PROT CONTROL SL/M	n/a n/a	0.055 - 2.1	0.0017 – 0.11 g/L	0.11 - 0.05° g/L	N FROT STANDARD SL		Pre-reaction
79 lq	lG4n	lgG Subclass 4	·	SMN 10445972	1 ×			N SUPPLEMENT P		N/T PROT CONTROL SL/H	n/a	0.052 – 3.3	0.0026 – 0.17 g/L	0.03 – 2.01º g/L	N PROT STANDARD SL	1.0	Fixed Time with
J			plasma; heparin plasma	N IGG4	1 ×	2 ml <b>nigg</b> 4) <b>reagent</b>		Cleaner SCS	_	N/T PROT CONTROL SL/M	n/a n/a		, , , , , , , , , , , , , , , , , , ,				Pre-reaction
2 lg	A	IgA			ıman IgA				[	N/T PROT CONTROL SL/L	n/a	0.25 – 8.0	0.25 – 8.0 g/L	0.7 – 4.0 <sup>g</sup> g/L	N PROT STANDARD SL	1.2	Fixed Time
			plasma; heparin plasma	NAS IGA	1 ×	5 mL	5/10 <sup>f</sup>		_	N/T PROT CONTROL SL/M	n/a n/a						
				SMN 10446295 REF OSAR11 SMN 10446293	1 ×	2 mL	3/6 <sup>f</sup>										
22 lg	As	lgA <sup>h</sup>	serum; EDTA plasma; heparin	N Antiserum to Hu NAS IGA	ıman IgA			N SUPPLEMENT P	-	N/T PROT CONTROL SL/L	n/a n/a	0.06 – 2.0	0.06 – 2.0 g/L	_9	N PROT STANDARD SL	1.3	Fixed Time
			plasma	<b>REF</b> OSAR19 SMN 10446295	1 ×	5 mL	5/10 <sup>f</sup>		[	N/T PROT CONTROL SL/H]	n/a						
2 1-		1-14		<b>REF</b> OSAR11 SMN 10446293	1 ×	2 mL	3/6 <sup>f</sup>			N/T PROT CONTROL SL/L					N PROT STANDARD SL	1 0	Final Time with
3 Ig	IM	lgM	serum; EDTA plasma; heparin plasma	N Antiserum to Hu NAS IGM REF OSAT19	ıman ığıvı 1 ×	Empl	5/10 <sup>f</sup>		[	N/T PROT CONTROL SL/M N/T PROT CONTROL SL/M N/T PROT CONTROL SL/H]	n/a n/a n/a	0.2 - 6.4	0.2 – 6.4 g/L	0.4 – 2.3 <sup>g</sup> g/L	N PROTISTANDARDISL		Fixed Time with Pre-reaction
			P	SMN 10446303 REF OSAT11	1 ×		3/6 <sup>f</sup>		Ľ		n/a						
23 lg	ıMs	lgM <sup>h</sup>			ıman lgM			N SUPPLEMENT P	p [	N/T PROT CONTROL SL/L	n/a	0.05 – 1.6	0.05 – 1.6 g/L	_9	N PROT STANDARD SL	1.3	Fixed Time
			plasma; heparin plasma	NAS IGM	1 ×	5 mL	5/10 <sup>f</sup>		-	N/T PROT CONTROL SL/M] N/T PROT CONTROL SL/H]	n/a n/a						
				SMN 10446303 REF OSAT11 SMN 10446301	1 ×	2 mL	3/6 <sup>f</sup>										
4 C	3	C3c	serum; EDTA plasma; heparin	N Antiserum to Hu N AS C3	ıman <mark>C3c</mark>					N/T PROT CONTROL SL/L	n/a n/a	0.12 – 4.1	0.03 – 1.0 g/L	0.9 – 1.8 <sup>i</sup> g/L	N PROT STANDARD SL	1.2	Fixed Time
			plasma	<b>REF</b> OSAP15 SMN 10446291	1 ×	5 mL	5/10 <sup>f</sup>		[	N/T PROT CONTROL SL/H	n/a						
F 6		64	EDTA	<b>REF</b> OSAP09 SMN 10446290	1 ×	2 mL	3/6 <sup>f</sup>		r			0.06	0.02		[	1.2	
5 C4	4	C4	serum; EDTA plasma; heparin plasma	NAS C4		Emi	5/10 <sup>f</sup>		[	N/T PROT CONTROL SL/L	n/a n/a	0.06 - 1.9	0.02 – 0.48 g/L	0.1 – 0.4 g/L	N PROT STANDARD SL	1.2	Fixed Time
			2.00710	REF OSAO15 SMN 10446289 REF OSAO09	1 × 1 ×	5 mL 2 mL	3/6 <sup>f</sup>		L	N/T PROT CONTROL SL/H	n/a						
6 TF	RF	Transferrin		SMN 10446288 N Antiserum to Hu					-	N/T PROT CONTROL SL/L	n/a	0.35 – 5.6	0.09 – 1.4 g/L	2.0 – 3.6 g/L	N PROT STANDARD SL	1.2	Fixed Time
			plasma; heparin plasma	N AS TRF	1 ×	5 mL	5/10 <sup>f</sup>		-	N/T PROT CONTROL SL/M] N/T PROT CONTROL SL/H]	n/a n/a						
				SMN 10446309 REF OSAX09 SMN 10446308	1 ×	2 mL	3/6 <sup>f</sup>										

SAN <sup>a</sup>	Abbr.	Protein	Specimen	Reagent	Supplements	Recommended Controls	Measuring Rang	-		Reference Range <sup>d</sup>	Standards	APV <sup>e</sup> Eval. Mode
				Package Quantity	On-board Stability <sup>b</sup> [days at 8 hours each]	On-board Stability <sup>b</sup> [days at 8 hours each]	On-board Condition Stability <sup>b</sup> [h]	Range Me	inimum Unit easuring Range	Condition	Unit	
7	ALB	Albumin	plasma; heparin	N Antiserum to Human Albumin N AS ALB		N/T PROT CONTROL SL/L	n/a n/a	6.9 – 110 0.35	– 5.5 g/L	35.0 – 52	.0 g/L N PROT STANDARD SL	1.2 Fixed Time
			plasma	REF         OSAL23         1 ×         2 mL           SMN 10714508         1 ×         5 mL	3/6 <sup>f</sup> 5/10 <sup>f</sup>	N/T PROT CONTROL SL/H	n/a					
	AAT	a <sub>1</sub> -Antitrypsin	serum; EDTA	SMN 10714509 N Antiserum to Human α <sub>1</sub> -Antitrypsin		N/T PROT CONTROL SL/L	n/a	0.16 – 5.2 0.04	– 1.3 g/L	0.9 – 2.	0 q/L N PROT STANDARD SL	1.2 Fixed Time
			plasma; heparin plasma	N AS AAT     REF OSAZ15     1 ×	5/10 <sup>f</sup>	N/T PROT CONTROL SL/M	n/a n/a					
				SMN 10446312 <b>REF</b> OSAZ09 1 × 2 mL SMN 10446311	3/6 <sup>f</sup>							
	a2M	$\alpha_2$ -Macroglobulin	serum; heparin	N Antiserum to Human $\alpha_2$ Macroglobulin N As[A2M]		N/T PROT CONTROL SL/L	n/a	0.2 – 6.4 0.05	– 1.6 g/L	1.3 – 3.	0 g/L NPROT STANDARD SL	1.2 Fixed Time
			plasma	REF OSAM21 1 × 5 mL SMN 10469773	5/10 <sup>f</sup>	N/T PROT CONTROL SL/H	n/a n/a					
0	HPT	Haptoglobin	serum; EDTA plasma; heparin	N Antiserum to Human Haptoglobin N AS HAPT		N/T PROT CONTROL SL/L	n/a n/a	0.26 – 8.3 0.07	– 2.1 g/L	0.3 – 2.	0 g/L N PROT STANDARD SL	1.2 Fixed Time
			plasma	REF         OSAV15         1 ×         5 mL           SMN 10446305	5/10 <sup>f</sup>	N/T PROT CONTROL SL/H	n/a					
1	AAG	a, acid	corum	<b>REF</b> OSAV09 $1 \times 2 \text{ mL}$ SMN 10446304N Antiserum to Human $\alpha_1$ -acid Glycoprotein	3/6 <sup>f</sup>	N/T PROT CONTROL SL/L	2/2	0.19 – 6.0 0.05	15 0/1	0.5 – 1.	2 g/L N PROT STANDARD SL	1.2 Fixed Time
11	AAG	α <sub>1</sub> -acid Glycoprotein	serum; heparin plasma	N AS[AAG]       REF OSAW15     1 ×     5 mL	5/10 <sup>f</sup>	N/T PROT CONTROL SL/L	n/a n/a	0.19 - 6.0 0.05	– 1.5 g/L	0.5 – 1.	Z GIL <u>N PROTISTANDARDISL</u>	1.2 Fixed filme
				SMN 10446307 REF OSAW09 1 × 2 mL	3/6 <sup>f</sup>		n/a					
12	PRE	Prealbumin	serum; heparin	SMN 10446306 N Antiserum to Human Prealbumin NAS PRE	N SUPPLEMENT P	b N/T PROT CONTROL SL/L	n/a	0.02 - 0.6 0.02	– 0.6 g/L	0.2 – 0.	4 g/L <b>N PROT STANDARD SL</b>	1.2 Fixed Time
			plasma	REF         OUIF09         1 ×         2 mL           SMN 10446452         10446452         10446452         10446452	3/6 <sup>f</sup>	N/T PROT CONTROL SL/M	n/a n/a					
13	sTfR	soluble Transferrin Receptor	serum; heparin plasma	N Latex sTfR N STFR		b N/T PROT CONTROL SL/L	n/a n/a	0.14 – 4.4 0.14	– 4.4 mg/L	0.76 – 1.7 sTfR/Ferritin-Index 0.38 – 1.5	· · · · · · · · · · · · · · · · · · ·	1.0 VLinIntegral
		Receptor	μαστια	REF         OQTC11         3 ×         2 mL           SMN 10446127         3 <td>5/10<sup>f</sup></td> <td>N/T PROT CONTROL SL/H</td> <td>n/a</td> <td></td> <td></td> <td></td> <td></td> <td></td>	5/10 <sup>f</sup>	N/T PROT CONTROL SL/H	n/a					
14	НРХ	Hemopexin	serum; heparin plasma	N Antiserum to Human Hemopexin N AS HPX		N/T PROT CONTROL SL/L	n/a n/a	0.2 – 6.4 0.05	– 1.6 g/L	0.5 – 1.1	I 5 g/L N PROT STANDARD SL	1.2 Fixed Time
1 5	CED	Comulo placesia		REF     OUVN09     1 ×     2 mL       SMN 10446493     SMN 10446493     SMN 10446493	3/6 <sup>f</sup>	N/T PROT CONTROL SL/H	n/a	0.07 2.2 0.02	0.55	0.2	6 g/L N PROT STANDARD SL	1.2 Fixed Time
D	CER	Ceruloplasmin	serum; heparin plasma	N Antiserum to Human Ceruloplasmin          N AS CER         REF OUIE09       1 ×       2 mL	3/6 <sup>f</sup>	N/T PROT CONTROL SL/M	n/a n/a	0.07 – 2.2 0.02	– 0.55 g/L	0.2 – 0.	6 g/L <u>IN PROTISTANDARDISL</u>	1.2 Fixed Time
6	RbP	Retinol-binding-	serum;	SMN 10446451 N Antiserum to Human RbP	3/6 <sup>°</sup>	N/T PROT CONTROL SL/H	n/a n/a	0.01 - 0.2 0.01	– 0.2 a/L	0.03 - 0.0	06 g/L <b>N PROT STANDARD SL</b>	1.2 Fixed Time
		Protein	heparin plasma	N AS RBP       REF OUVO09     1 ×     2 mL	3/6 <sup>f</sup>	N/T PROT CONTROL SL/M	n/a n/a					
7	kap		serum	SMN 10446494 N Antiserum to Human lg/L-chain, κ-type		N/T PROT CONTROL SL/L	n/a	0.28 – 9.1 0.07	– 2.3 g/L	1.7 – 3.7	79 g/L <b>N PROT STANDARD SL</b>	1.2 Fixed Time
		карра		N AS KAPPA           REF         OWHG13         1 ×         2 mL           SMN 10446595         10446595         10446595	3/6 <sup>f</sup>	N/T PROT CONTROL SL/M	n/a n/a			Adults' Ig/L-chains quotient κ/λ (Hu- 1.35 – 2.6 man serum)	55 <sup>k</sup>	
80	FLC_K	free lg/L-chain, type kappa	plasma;	N Latex FLC kappa	N FLC SUPPLEMENT	b [N FLC] [CONTROL  SL1]	n/a n/a	3.4 – 110 0.17	– 5.5 mg/L	8.24 – 28. Adults' free lg/L-	9 <sup>g</sup> mg/L <b>N FLC STANDARD SL</b>	2.0 Fixed Time wi Pre-reaction
			heparin plasma	REF OPJA07 3 × 1.7 mL SMN 10873629	5/6 <sup>f</sup>					chains quotient κ/λ (Human se- 0.53 – 1. rum), 1 <sup>th</sup> –99 <sup>th</sup>	51 <sup>k</sup>	
18	lam	lg/L-chain, type lambda	serum	N Antiserum to Human lg/L-chain, λ-type N AS LAMBDA		N/T PROT CONTROL SL/L	n/a n/a	0.16 – 5.0 0.04	– 1.3 g/L	percentile 0.9 – 2.1 Adults' Ig/L-chains	5	1.2 Fixed Time
				REF         OWHH13         1 ×         2 mL           SMN 10446597         10446597         10446597	3/6 <sup>f</sup>	N/T PROT CONTROL SL/H	n/a			quotient κ/λ (Hu- 1.35 – 2.6 man serum)	55 <sup>k</sup>	
31	FLC_L	free lg/L-chain, type lambda	plasma; heparin	N Latex FLC lambda N FLC LAMBDA	N FLC SUPPLEMENT Cleaner SCS	<ul> <li>b N FLC CONTROL SL1</li> <li>5 N FLC CONTROL SL2</li> </ul>	n/a n/a	1.9 – 60 0.48	– 15 mg/L	9.10 – 32. Adults' free lg/L- chains quotient	6 <sup>g</sup> mg/L <b>N FLC</b> STANDARD SL	4.0 Fixed Time w Pre-reaction
			plasma	REF         OPJB07         3 ×         2.1 mL           SMN 10873630	5/6 <sup>f</sup>					chains quotient $\kappa/\lambda$ (Human se- 0.53 – 1. rum), 1 <sup>th</sup> –99 <sup>th</sup> percentile	51 <sup>k</sup>	

	Abbr.	Protein	Specimen	Reagent				Supplements		Recommended Controls	Measuring Range <sup>c</sup>			Reference Range <sup>d</sup>	Standards	APV <sup>e</sup> Eval. Mode
				Package (	Quantity		On-board Stability <sup>b</sup> [days at 8 hours each]		On-board Stability <sup>b</sup> [days at 8 hours each]		On-board Condition Stability <sup>b</sup> [h]	Initial Measuring Range	Minimum Unit Measuring Range	Condition Un	t	
0	A-I	Apolipoprotein A-I	serum; heparin plasma	N Antiserum to Hum N AS APOAI REF OUED15	an Apolipoproto 1 × 5 r	tein A-I	_	N SUPPLEMENT P		APO CONTROL CHD	n/a	0.19 – 6.0	0.05 – 1.5 g/L	1.15     -     2.1 <sup>1</sup> g/L       men     1.10     -     2.05     g/L       women     1.25     -     2.15     g/L	N APO STANDARD	1.1 Fixed Time
				SMN 10446438 REF OUED09 SMN 10446437	1 × 2 r		3/6 <sup>f</sup>							men (Apo B/ Apo A-l quotient) 0.35 – 1.0 <sup>k</sup> women (Apo B/ Apo A-l quotient) 0.3 – 0.9 <sup>k</sup>		
l	АроВ	Apolipoprotein B	serum; heparin plasma	N Antiserum to Hum N AS APOB				N SUPPLEMENT P	b	APO CONTROL CHD	n/a	0.25 – 4.0	0.25 – 4.0 g/L	App A-i quotient)         0.55         –         1.35 <sup>I</sup> g/L           men         0.55         –         1.40         g/L           women         0.55         –         1.25         g/L		1.2 Fixed Time
				REF OSAN15 SMN 10446287 REF OSAN09 SMN 10446286	1 × 5 r 1 × 2 r		5/10 <sup>f</sup> 3/6 <sup>f</sup>							men (Apo B/ Apo A-l quotient) 0.35 – 1.0 <sup>k</sup> women (Apo B/		
9	Lpa	Lipoprotein(a)	serum; heparin plasma	N Latex Lp(a) Reager	it					N LP(A) CONTROL SY	n/a	0.1 – 1.6	0.03 – 0.4 g/L	Apo A-I quotient) 0.3 – 0.9 × <0.3 <sup>1</sup> g/L caucasian, men <0.02 – 0.74 g/L	N LP(A) STANDARD SY	4.0 Fixed Time
			ризтиа	REF OQHL11 SMN 10446069	3 × → 2 r	mL	5/10 <sup>f</sup>							caucasian, women <0.02 – 0.72 g/L african-american, 0.04 – 1.14 g/L african-american, 0.02 – 1.08 g/L women 0.02 – 0.53 g/L can, men 0.02 – 0.53 g/L		
50	FDT	Courisin		N.Lotov Forsitio							2/2	10 (40	25 160	hispanic-ameri- 0.02 – 0.46 g/L can, women		
50	FRT	Ferritin	serum; heparin plasma	N Latex Ferritin						N/T PROT CONTROL SL/L	n/a n/a	10 – 640	2.5 – 160 μg/L	10 – 250 <sup>i</sup> μg/ men 20 – 290 μg/		8.0 VLinIntegral
				REF OQTH11 SMN 10446130	3× 1 r	mL <b>N FRT REAGENT</b> mL <b>N FRT SUPPLEMENT A</b> mL <b>N FRT SUPPLEMENT B</b>	5/10 <sup>f</sup> ь			N/T PROT CONTROL SL/H	n/a			women, premeno- pausal 4.5 – 170 μg/ women, postme- nopausal 24 – 260 μg/ sTfR/Ferritin-Index 0.38 – 1.54 <sup>k</sup>		
34	RFn	RF	serum; EDTA plasma; heparin	N Latex RF Kit <b>N RF</b>						N/T RHEUMA CONTROL SL/1	n/a n/a	10 – 640	10 – 640 IU/mL	< 15.9 IU/r	nL <b>N RHEUMA STANDARD SL</b>	1.0 VLinIntegral
			plasma	REF OPCE03 SMN 10445991 REF OPCE05 SMN 10445992	3 × 2.4 r 4 × 4 r	mL <b>N RF REAGENT</b> mL <b>N RF SUPPLEMENT</b> mL <b>N RF REAGENT</b> mL <b>N RF SUPPLEMENT</b>	nr <sup>m</sup> /5 <sup>f</sup> b nr <sup>m</sup> /5 <sup>f</sup> b									
85	ASLn	ASL	serum; EDTA plasma; heparin plasma	N Latex ASL NASL REF OPBU03	3× 2 r		7/10 <sup>f</sup>	N SUPPLEMENT P	b	N/T RHEUMA CONTROL SL/1	n/a n/a	50 – 1600	13 – 400 IU/mL	caucasian < 408 IU/r	nL <b>In Rheuma   Standard   Sl</b>	1.1 Fixed Time
				SMN 10445983 REF OPBU05 SMN 10445984	4 × 3.5 r		7/10 <sup>f</sup>									
42	CRP2	CRP sensitive	serum; EDTA plasma; heparin plasma	CardioPhase® hsCRP REF OQIY13 SMN 10446090	3 × 2 r	mL CardioPhase hsCRP [ <b>REAGENT</b> ]	5/10 <sup>f</sup>	N SUPPLEMENT P	b	APO CONTROL CHD	n/a	0.16 – 10	0.16 – 10 mg/L	< 5 mg	L N RHEUMA STANDARD SL	5.0 VLinIntegral
				<b>REF</b> OQIY21 SMN 10446091	5× 5 r	mL CardioPhase hsCRP [REAGENT]	5/10 <sup>f</sup>									
'1	CRP1	CRP	serum; EDTA plasma; heparin plasma	CardioPhase <sup>®</sup> hsCRP REF OQIY13 SMN 10446090	3 × 2 r	mL CardioPhase hsCRP	5/10 <sup>f</sup>	N SUPPLEMENT P	b	N/T RHEUMA CONTROL SL/1	n/a n/a	3.1 – 200	0.16 – 10 mg/L	< 5 mg	L N RHEUMA STANDARD SL	5.0 VLinIntegral
				<b>REF</b> OQIY21 SMN 10446091	5× 5 r	mL CardioPhase hsCRP REAGENT	5/10 <sup>f</sup>									
57	lgE1	lgE	plasma; heparin	N IGE				N SUPPLEMENT L	b	N/T PROT CONTROL SL/L	n/a n/a	18 – 1150	4.5 – 290 IU/mL	< 100 <sup>g</sup> 1U/r	N PROT STANDARD SL	3.1 VLinIntegral
8	ADNs	ADNase B	plasma serum	REF OQTG15 SMN 10446129 N Latex ADNase B	3× 3r	mL	5/10 <sup>f</sup>			N/T PROT CONTROL SL/H	n/a n/a	75 - 3000	75 – 3000 U/mL	< 200 IU/i	nL <b>N ADNS</b> STANDARD <sup>n</sup>	1.1 Fixed Time
				<b>N ADNS REF</b> 10873691 (OWTI15)	3× 1 r 3× 2 r	mL <b>N ADNS REAGENT</b> mL <b>N ADNS STANDARD</b> mL <b>N ADNS CONTROL</b> mL <b>N ADNS SUPPLEMENT</b>	nr/nr <sup>f</sup>			, <u>,</u> ,						
59	b2M	$\beta_2$ -Microglobulin	plasma; heparin	N Latex β <sub>2</sub> -Microglob Ν <b>Β2Μ</b>	oulin			N SUPPLEMENT L	b	N/T PROT CONTROL SL/M	n/a n/a	0.7 – 23	0.18 – 5.8 mg/L	1.09 – 2.53 mg	L N PROT STANDARD SL	3.0 VLinIntegral
			plasma	<b>REF</b> OQWU21 SMN 10446162		mL <b>N B2M REAGENT</b> mL <b>N B2M U STAB</b>	5/10 <sup>f</sup>									

SAN <sup>a</sup> Abbr.	Protein	Specimen	Reagent			Supplements	Recommended Controls	Measuring Range <sup>c</sup>			Reference Range		Standards	APV <sup>e</sup>	Eval. Mode
			Package	Quantity	On-board Stability <sup>b</sup>	On-board Stability <sup>b</sup>		On-board Condition Stability <sup>b</sup>	Initial Measuring Range	Minimum Unit Measuring	Condition	Unit			
					[days at	[days at	t	[h]	Range	Range					
) MYO	Myoglobin	serum: FDTA	N Latex Myoglobin		8 hours each]	8 hours each]		n/a	25 – 400	6.3 – 100 μg/L		< 70 μg/L	N MYO STANDARD <sup>n</sup>	1.1	Fixed Time
		plasma; heparin	N MYO							3.0 100 μg/L					inter fille
		plasma	<b>REF</b> 10873690	3 × → 2 mL NMYO REAGENT	3/5 <sup>f</sup>										
			(OWIA17)	$3 \times \rightarrow 1 \text{ mL}$ <b>N MYO STANDARD</b>											
				$3 \times \rightarrow 0.5 \text{ mL}$ <b>N MYO CONTROL</b> $3 \times 0.5 \text{ mL}$ <b>N MYO SUPPLEMENT A</b>	b										
				3 × 1.6 mL NMYO SUPPLEMENT B											
56 CysC	Cystatin C	serum; heparin	N Latex Cystatin C			Cleaner SCS 5		n/a	0.27 – 9.4	0.27 – 9.4 mg/L		0.49 – 1.19 mg/L	N PROT STANDARD UY	3.0	Fixed Time
		plasma			5/10 <sup>f</sup>		N CYSC CONTROL 2 <sup>n</sup>	n/a							
			<b>REF</b> OQNM19 SMN 10873631	$3 \times 2 \text{ mL } \text{N CYSC } \text{REAGENT}$ $3 \times \rightarrow 1 \text{ mL } \text{N CYSC } \text{CONTROL } 1$	5/10										
				3 × → 1 mL NCYSC CONTROL 2											
				3 ×         0.5 mL         N CYSC         SUPPLEMENT A           1 ×         1.6 mL         N CYSC         SUPPLEMENT B	b										
75 HCY	Homocysteine	serum; EDTA	N Latex HCY				N/T PROT CONTROL SL/L	n/a	2 – 64	2 – 64 µmol/L	EDTA plasma	4.9 – 15.0 μmol/L	N PROT STANDARD SL	2.2	Fixed Time
	ŗ	plasma; heparin	N HCY				N/T PROT CONTROL SL/M	n/a			·				
		plasma		3 × 1.7 mL NHCY REAGENT	3/6 <sup>f</sup>		N/T PROT CONTROL SL/H	n/a							
			SMN 10445973	3 × 2.2 mL NHCY RA 3 × 0.6 mL NHCY SR A	3/6 <sup>f</sup>										
				3 × 1.1 mL NHCY SR B											
7 CDT	Carbohydrate- deficient	serum	N Latex CDT Kit				N CDT CONTROL 1 <sup>n</sup>	n/a	20 – 660°	20 – 660 mg/L	1 <sup>th</sup> –99 <sup>th</sup> percen- tile	28.1 – 76.0 <sup>p</sup> mg/L	N CDT STANDARD <sup>n</sup>	1.0	Fixed Time
	Transferrin				- ust		N CDT CONTROL 2 <sup>n</sup>	n/a			the				
			<b>REF</b> OPCS05 SMN 10445997	3 × 0.9 mL N CDT REAGENT 1 3 × 0.9 mL N CDT REAGENT 2	3/6 <sup>f</sup> 3/6 <sup>f</sup>										
				3 × 2 mL NCDT SUPPLEMENT	Ь										
				3 ×         1 mL         N CDT         STANDARD           3 ×         1 mL         N CDT         CONTROL         1	n/a										
				$3 \times 1 \text{ mL} \text{ [N CDT] [CONTROL] 1}$ $3 \times 1 \text{ mL} \text{ [N CDT] [CONTROL] 2}$	7 days										
0 C1I	C1-Inhibitor	serum;	N Antiserum to Hur	nan C1-Inhibitor		N SUPPLEMENT P	N/T PROT CONTROL PY	n/a	0.03 - 0.4	0.03 – 0.4 g/L	serum	0.21 – 0.39 <sup>i</sup> g/L	N PROT STANDARD PY	1.2	Fixed Time
		citrated plasma	N AS C1IN								citrated plasma	0.18 – 0.32 g/L			
			<b>REF</b> OQEY09 SMN 10446049	1 × 2 mL	3/6 <sup>f</sup>										
40 FIB	Fibrinogen	EDTA	N Antiserum to Hur	nan Fibrinogen		N SUPPLEMENT P		n/a	0.59 – 9.4	0.15 – 2.4 g/L	citrated plasma	1.8 – 3.50 g/L	N PROT STANDARD PY	1.1	Fixed Time
		plasma; citrated	N AS FIB												
		plasma	<b>REF</b> OSCA09 SMN 10446313	1 × 2 mL	3/6 <sup>f</sup>										
41 AT3	Antithrombin III	EDTA	N Antiserum to Hur	nan Antithrombin III		N SUPPLEMENT P	N/T PROT CONTROL PY	n/a	0.03 – 0.54	0.03 – 0.54 g/L	citrated plasma	0.19 – 0.31 g/L	N PROT STANDARD PY	1.2	Fixed Time
		plasma; citrated	N AS ATIII												
		plasma	<b>REF</b> OSAY09 SMN 10446310	1 × 2 mL	3/6 <sup>f</sup>										
43 PLS	Plasminogen	EDTA	N Antiserum to Hur	nan Plasminogen		N SUPPLEMENT P		n/a	0.01 – 0.2	0.01 – 0.2 g/L	citrated plasma	0.06 – 0.25 g/L	N PROT STANDARD PY	1.2	Fixed Time
		plasma; citrated	N AS PLS												
		plasma	<b>REF</b> OSCB09 SMN 10446314	1 × 2 mL	3/6 <sup>f</sup>										
21 lgGU	lgG	urine	N Antiserum to Hur	nan IgG			N/T PROT CONTROL LC	n/a	3.6 – 58	3.6 – 58 mg/L	second morning		N PROT STANDARD SL	1.2	Fixed Time
.9-0			NAS IGG								urine	< 9.6 mg/L			
			<b>REF</b> OSAS19	1 × 5 mL	5/10 <sup>f</sup>										
			SMN 10446299 <b>REF</b> OSAS11	1 × 2 mL	3/6 <sup>f</sup>										
			SMN 10446297		510										
26 TRFU	Transferrin	urine	N Antiserum to Hur <b>N AS TRF</b>	nan Transferrin			N/T PROT CONTROL LC	n/a	2.2 – 35	2.2 – 35 mg/L		_q	N PROT STANDARD SL	1.2	Fixed Time
			REF OSAX15	1 × 5 mL	5/10 <sup>f</sup>										
			SMN 10446309		יטרוכ										
			REF OSAX09	1 × 2 mL	3/6 <sup>f</sup>										
27 ALBU	Albumin	urine	SMN 10446308 N Antiserum to Hur	nan Albumin			N/T PROT CONTROL LC	n/a	11 - 340	2.2 – 68 mg/L		< 30 ma/l	N PROT STANDARD SL	1.1	Fixed Time
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			N AS ALB							00 mgre					Pre-reaction
			REF OSAL23	1 × 2 mL	3/6 <sup>f</sup>										
			SMN 10714508 <b>REF</b> OSAL25	1 x 5 ml	5/10 <sup>f</sup>										
			REF OSAL25 SMN 10714509	1 × 5 mL	5/10'										
29 a1MU	α <sub>1</sub> -Microglobulin	urine	N a <sub>1</sub> -Microglobulin	Kit			N/T PROT CONTROL LC	n/a	5.6 – 180	5.6 – 180 mg/L	second morning urine	< 12 mg/L	N PROT STANDARD UY	1.2	Fixed Time
					- · - !							-			
			<b>REF</b> OWLA11 SMN 10446619	1 × 2 mL NASA1M 1 × 2 mL NSUPPLEMENTA	3/6 <sup>f</sup>										

AN <sup>a</sup> Abbr.	Protein	Specimen	Reagent		Supplements	Recommended Controls	Measuring Rai	nge <sup>c</sup>	Reference Range <sup>d</sup>	Standards	APV <sup>e</sup>	Eval. Mode
			Package	Quantity	On-board Stability <sup>b</sup> [days at 8 hours each]	On-board Stability <sup>b</sup> [days at 8 hours each]	On-board Condition Stability <sup>b</sup> [h]	-		nit		
3 b2MU	$\beta_2$ -Microglobulin	urine	N Latex β <sub>2</sub> -Microg <b>N B2M</b> <b>REF</b> OQWU21 SMN 10446162	globulin 3 × 3 mL N B2M REAGENT 1 × 2 mL N B2M U STAB	N SUPPLEMENT L	b [N/T PROT CONTROL SL/L] [N/T PROT CONTROL SL/M]	n/a n/a	0.2 – 5.8 0.2 – 5.8 m	ng/L _q	N PROT STANDARD SL	3.0	VLinIntegral with Pre-reaction
1 lgGC	IgG	CSF	N Antiserum to H NAS IGG REF OSAS19 SMN 10446299 REF OSAS11 SMN 10446297		5/10 <sup>f</sup> 3/6 <sup>f</sup>	N/T PROT CONTROL LC	n/a	3.6 – 115 3.6 – 115 m	ng/L < 34 m	g/L <u>N prot standard sl</u>	1.4	Fixed Time
2 IgAC	IgA	CSF serum	N Latex IgA N IGA N IGA REF OQAI15 SMN 10873689	$3 \times \rightarrow 2 \text{ mL } \text{N IGA } \text{REAGENT}$ $3 \times \rightarrow 1 \text{ mL } \text{N IGA } \text{STANDARD}$ $3 \times \rightarrow 1 \text{ mL } \text{N IGA } \text{CONTROL}$ $3 \times 1 \text{ mL } \text{N IGA } \text{SUPPLEMENT } \text{A}$ $1 \times 0.4 \text{ mL } \text{N IGA } \text{SUPPLEMENT } \text{B}$	3/6 <sup>f</sup> b	N/T PROT CONTROL LC	n/a CSF n/a serum	1.25 – 41.5 0.25 – 8.3 m 500 – 16600 100 – 3300 m	0	g/L <b>NIGA STANDARD</b> <sup>n</sup>	1.1	Fixed Time
3 IgMC	lgM	CSF	N Latex lgM N IGM REF OQAC15 SMN 10873688	$3 \times \rightarrow 2 \text{ mL } \text{N IGM } \text{REAGENT}$ $3 \times \rightarrow 1 \text{ mL } \text{N IGM } \text{STANDARD}$ $3 \times \rightarrow 1 \text{ mL } \text{N IGM } \text{CONTROL}$ $3 \times 1 \text{ mL } \text{N IGM } \text{SUPPLEMENT } \text{A}$ $1 \times 0.4 \text{ mL } \text{N IGM } \text{SUPPLEMENT } \text{B}$	nr/5 <sup>f</sup> n/a b	N/T PROT CONTROL LC	n/a CSF n/a	0.13 – 4.2 0.13 – 4.2 m	ng/L CSF < 1.3 m	g/L <b>N IGM STANDARD</b> <sup>n</sup>	1.0	Fixed Time
7 ALBC	Albumin	CSF	N Antiserum to H N AS ALB REF OSAL23 SMN 10714508 REF OSAL25 SMN 10714509		3/6 <sup>f</sup> 5/10 <sup>f</sup>	N/T PROT CONTROL LC	n/a	86 – 1375 17 – 275 m	ng/L < 350 m	g/L <b>N PROT STANDARD SL</b>	1.4	Fixed Time
conditions an figures derive product speci monitor reag according to employing a	bility depends on envir d fill volume. These ar d from internal studies fications. It is recomm ent stability by running the Instruction for Use supplementary reagen ent and the respective	e typical s but no ended to g controls . For assays t the figures	Results wi can be an (integrate d Literature	t measuring range depends on the value of the relevant standard lot. hich are outside the measuring range halyzed using a different sample dilution ed in the software). e references are given in the Instructions f the relevant reagent. tocol Version	<ul> <li>f Extended reagent on-board stability of achieved by using BN II Evaporation S</li> <li>REF OVLE21, which must be used in with COVER RING EVAP. STOPPERS, SMN 11255073.</li> <li>9 Pediatric reference ranges for IgG, IgG IgA, IgM, IgE, Ig/L-chains and free Ig/I serum are dependent on age and car wide range.</li> </ul>	toppers, combination 5 subclasses, -chains in attent samples which require measuring range. A lower reference range applies A new reference curve must be relevant tests if the lot of the N Reagent L is changed.	a lower n Comp o The n to fresh samples. than generated for the P The % Supplementary refere Antise 1.19 f	ecommended bonent is part of the Reagent Kit. nanual selection of another sample dilution 1:5 is not permissible. 6 CDT values in this population, with ence to the results obtained with the N erum to Human Transferrin, ranged from to 2.47 % CDT (1 <sup>th</sup> to 99 <sup>th</sup> percentile).	<ul> <li><sup>q</sup> Concentration of the analyte in the urine of healthy individuals is below the detection lin this method.</li> <li><sup>r</sup> IgG and Albumin in serum and CSF can also analyzed using a single reference curve, pro that the appropriate serum sample dilution selected manually.</li> </ul>	mit of be wided		

## **Volumes and Dilutions**

SAN <sup>s</sup>	Abbr.	Protein	Standard Dilutions <sup>t</sup>		Sample Dilution <sup>t</sup>	Sample	Reagent	Supplements	Buffer for Sample	Buffer for Reagent	Reaction	
				Count Range	Specimen	Initial Minimal	Volume [µL]	Volume [μL]	Volume [μL]	Volume [μL]	Volume Ti [µL]	ime [min]
1	lgG	lgG	N PROT STANDARD SL	6 1:80-1:2560	serum; EDTA plasma; heparin plasma	1:400 1:20	100 NASIGG	40		100	60	6
51	lgG1	IgG Subclass 1	N PROT STANDARD SL	6 1:20–1:640	serum; EDTA plasma;	1:100 1:5	25 <b>N AS IGG1</b>	40		70	70	6
52	lgG2	lgG Subclass 2	N PROT STANDARD SL	6 1:5–1:160	heparin plasma serum; EDTA plasma;	1:20 1:5	25 <b>N AS IGG2</b>	40 <b>N SUPPLEMENT P</b>	10	70	70	12
78	lgG3n	IgG Subclass 3	N PROT STANDARD SL	7 1.320-1.20480	heparin plasma serum; EDTA plasma;	1:2000 1:100	5 + 35 <b>N IGG3 REAGENT</b>	55 <b>N SUPPLEMENT P</b>	25 N DILUENT	55 + 15 <b>N DILUENT</b>	70	2 + 6
70					heparin plasma							
79	lgG4n	lgG Subclass 4	N PROT STANDARD SL	7 1:320–1:20480	serum; EDTA plasma; heparin plasma	1:2000 1:100	5 + 50 <b>N IGG4 REAGENT</b>	50 <b>N SUPPLEMENT P</b>	25 N DILUENT	55 + 10 <b>N DILUENT</b>	75	2 + 6
2	lgA	lgA	N PROT STANDARD SL	6 1:5–1:160	serum; EDTA plasma; heparin plasma	1:20 1:20	20 NAS IGA	40		80	80	6
22	IgAs	lgA <sup>u</sup>	N PROT STANDARD SL	6 1:5–1:160	serum; EDTA plasma; heparin plasma	1:5 1:5	20 NASIGA	40 <b>N SUPPLEMENT</b> P	30	80	50	6
3	lgM	lgM	N PROT STANDARD SL	6 1:2.5–1:80	serum; EDTA plasma;	1:20 1:20	5 + 45 <b>NAS</b> IGM	40		55 + 30	100	2 + 4
23	lgMs	lgM <sup>u</sup>	N PROT STANDARD SL	6 1:2.5–1:80	heparin plasma serum; EDTA plasma;	1:5 1:5	50 NAS IGM	40 <b>N SUPPLEMENT P</b>	30	80	50	6
٨					heparin plasma serum; EDTA plasma;	1:20 1:5	20 <b>NAS</b> C3			80		6
4	C3	C3c	N PROT STANDARD SL		heparin plasma			40			80	0
5	C4	C4	N PROT STANDARD SL	6 1:2.5–1:80	serum; EDTA plasma; heparin plasma	1:20 1:5	100 <b>NAS</b> C4	40		100	60	6
6	TRF	Transferrin	N PROT STANDARD SL	5 1:10–1:160	serum; EDTA plasma; heparin plasma	1:20 1:5	10 NASTRF	40		80	80	6
7	ALB	Albumin	N PROT STANDARD SL	5 1:160-1:2560	serum; EDTA plasma;	1:400 1:20	15 NASALB	30		100	130	6
8	AAT	α <sub>1</sub> -Antitrypsin	N PROT STANDARD SL	6 1:5–1:160	heparin plasma serum; EDTA plasma;	1:20 1:5	20 <b>NAS AAT</b>	40		80	80	6
9	a2M	α <sub>2</sub> -Macroglobulin	N PROT STANDARD SL	6 1.2-1.160	heparin plasma serum; heparin plasma	1:20 1:5	20 <b>N AS A2M</b>	40		80	80	6
10	HPT	Haptoglobin	N PROT STANDARD SL		serum; EDTA plasma;	1:20 1:5	10 <b>NAS</b> HAPT	40		80	80	6
11	AAG	α <sub>1</sub> -acid Glycoprotein	N PROT STANDARD SL	6 1:2.5–1:80	heparin plasma serum; heparin plasma	1:20 1:5	15 <b>NAS AAG</b>	30		125	125	6
12	PRE	Prealbumin	N PROT STANDARD SL	6 1:2.5–1:80	serum; heparin plasma		50 <b>NAS PRE</b>	40 N SUPPLEMENT P	30	100	60	6
13	sTfR	soluble Transferrin Receptor	N PROT STANDARD SL	6 1:5–1:160	serum; heparin plasma	1:20 1:20	70 N STFR	60 <b>N SUPPLEMENT L</b>	30 N DILUENT	40 <b>N DILUENT</b>	30	6
14	HPX CER	Hemopexin Ceruloplasmin	N PROT STANDARD SL		serum; heparin plasma serum; heparin plasma	1:20 1:5 1:20 1:5	20 <b>N AS HPX</b> 100 <b>N AS CER</b>	40 40		80 100	80 60	6
16	RbP	Retinol-binding-Protein	N PROT STANDARD SL		serum; heparin plasma	1:5 1:5	50 <b>NAS RBP</b>	40 <b>N SUPPLEMENT P</b>	10	100	60	6
17	kap	lg/L-chain, type kappa	N PROT STANDARD SL		serum	1:20 1:5		30		80	80	6
80	FLC_K	free Ig/L-chain, type kappa	N FLC STANDARD SL		serum; EDTA plasma; heparin plasma	1:100 1:5	8 + 75 <b>N FLC KAPPA</b>	45 <b>N FLC SUPPLEMENT</b>	15 <b>N DILUENT</b>	55 + 5 <b>N DILUENT</b>	90	2 + 10
18 81	lam FLC_L	lg/L-chain, type lambda free lg/L-chain, type	N PROT STANDARD SL	6 1:5–1:160 6 1:10–1:320	serum serum; EDTA plasma;	1:20 1:5 1:20 1:5	10 <b>N AS LAMBDA</b> 7 + 55 <b>N FLC LAMBDA</b>	40 55 <b>N FLC</b> SUPPLEMENT	15 N DILUENT	80 50 + 5 <b>N DILUENT</b>	80 95	6 3 + 10
20		lambda			heparin plasma							
30	A-I ApoB	Apolipoprotein A-I Apolipoprotein B	N APO STANDARD		serum; heparin plasma serum; heparin plasma	1:20     1:5       1:20     1:20	10 <b>N AS APOAI</b> 30 <b>N AS APOB</b>	40N SUPPLEMENT   P40N SUPPLEMENT   P	10	80 80	80 70	6
39	Lpa	Lipoprotein(a)	N LP(A) STANDARD SY		serum; heparin plasma	1:400 1:100	30 <b>N LP(A) REAGENT</b>	50	N DILUENT	60 N DILUENT	60	6
50	FRT	Ferritin	N PROT STANDARD SL	7 1:10-1:640	serum; heparin plasma	1:20 1:5	120 <b>N FRT REAGENT</b>	40 <b>N FRT SUPPLEMENT A</b> + <b>N FRT SUPPLEMENT B</b>	25 N DILUENT	85 N DILUENT	40	6
84	RFn	RF	N RHEUMA STANDARD SL	7 1:5–1:320	serum; EDTA plasma; heparin plasma	1:20 1:20	20 NRF REAGENT	50 <b>N RF SUPPLEMENT</b>	60 <b>N DILUENT</b>	60 <b>N DILUENT</b>	40	6
85	ASLn	ASL	N RHEUMA STANDARD SL	6 1:40-1:1280	serum; EDTA plasma; heparin plasma	1:400 1:100	70 <b>NASL</b>	40 <b>N SUPPLEMENT P</b>	50 <b>N DILUENT</b>	40 <b>N DILUENT</b>	50	6
42	CRP2	CRP sensitive	N RHEUMA STANDARD SL	7 1:40-1:2560	serum; EDTA plasma;	1:20 1:20	40 CardioPhase hsCRP <b>REAGENT</b>	40 <b>N SUPPLEMENT</b> P	5 N DILUENT	70 <b>N DILUENT</b>	60	6
71	CRP1	CRP	N RHEUMA STANDARD SL	7 1:40-1:2560	heparin plasma serum; EDTA plasma;	1:400 1:20	40 CardioPhase hsCRP <b>REAGENT</b>	40 N SUPPLEMENT P	5 N DILUENT	70 <b>N DILUENT</b>	60	6
57	lgE1	lgE	N PROT STANDARD SL	7 1.10-1.640	heparin plasma serum; EDTA plasma;	1:20 1:5	80 <b>NIGE</b>	60 N SUPPLEMENT L	20 N DILUENT	30 N DILUENT	40	6
57	-				heparin plasma							U
58 59	ADNs b2M	ADNase B β <sub>2</sub> -Microglobulin	N ADNS STANDARD V	6 1:1–1:40 6 1:20–1:640	serum serum; EDTA plasma;	1:5 1:5 1:400 1:100	20 <b>N ADNS REAGENT</b> 50 <b>N B2M REAGENT</b>	50N ADNSSUPPLEMENT70N SUPPLEMENTL	70N DILUENT15N DILUENT	50N DILUENT55N DILUENT	50 70	12 6
60	MYO	Myoglobin			heparin plasma serum; EDTA plasma;	1:20 1:5	80 <b>N MYO REAGENT</b>	75 <b>N MYO</b> SUPPLEMENT A		75	75	10
00	MITO	муодюын	[N MYO] [STANDARD]"		heparin plasma		OU INMITO REAGENT	+ N MYO SUPPLEMENT B	20		75	12
66	CysC	Cystatin C	N PROT STANDARD UY	6 1:20–1:640	serum; heparin plasma	1:100 1:100	30 N CYSC REAGENT	40 N CYSC SUPPLEMENT A + N CYSC SUPPLEMENT B	10 ILUENT	60 N DILUENT	20 80	6
75	HCY	Homocysteine	N PROT STANDARD SL	6 1:5–1:160	serum; EDTA plasma;	1:5 1:5	14 NHCY REAGENT	42 <b>NHCY</b> SR A	42 N DILUENT	42 N DILUENT	84	12
77	CDT	Carbohydrate-deficient		6 1:2.5–1:80	heparin plasma	1:5 <sup>w</sup> 1:5	N HCY     RA       24     N CDT     REAGENT 1	56 + NHCY SR B 30 N CDT SUPPLEMENT	65 <b>N SUPPLEMENT</b> L	N DILUENT       20     N DILUENT	42 50	18
//		Transferrin		0 1.2.3-1.00	Jerum	6.1 6.1	N CDT REAGENT 1	30 [N CDT][SUPPLEMENT] 30		10 <b>N DILUENT</b>	60	10
70	C1I	C1-Inhibitor			serum; citrated plasma	1:5 1:5 1:20 1:5		40 N SUPPLEMENT P	30	100	60	6
40	FIB	Fibrinogen	N PROT STANDARD PY		EDTA plasma; citrated plasma	1:20 1:5	20 NAS FIB	40 N SUPPLEMENT P	30	80	80	6
41	AT3	Antithrombin III	N PROT STANDARD PY	5 1:2.5–1:40	EDTA plasma; citrated plasma	1:5 1:5	100 NASATIII	40 <b>N SUPPLEMENT P</b>	30	100	60	6
	DLC	Plasminogen	N PROT STANDARD PY	5 1:2.5–1:40	EDTA plasma; citrated	1:5 1:5	100 NAS PLS	40 <b>N SUPPLEMENT P</b>	30	100	60	6
43	PLS				plasma							1

SAN <sup>s</sup>	Abbr.	Protein	Standard Dilutions <sup>t</sup>		Sample Dilutio	n <sup>t</sup> Samp	ole Reagent	Supplements	Buffer for Sample	Buffer for Reagent	R	Reaction
				Count	Range Specimen	Initial Minimal	Volume [µL]	Volume [µL]	Volume [µL]	Volume [µL]	Volume [μL]	Time [min]
26	TRFU	Transferrin	N PROT STANDARD SL	5 1:80-1	:1 280 urine	1:1 1:1	100 NASTRF	40		100	60	6
27	ALBU	Albumin	N PROT STANDARD SL	6 1:640–1:	20480 urine	1:5 1:1	5 + 95 <b>NAS ALB</b>	40		55 + 30	100	2 + 4
29	a1MU	a <sub>1</sub> -Microglobulin	N PROT STANDARD UY	6 1:2.5	5–1:80 urine	1:1 1:1	20 <b>NASA1M</b>	40 N SUPPLEMENT A	10	90	70	6
73	b2MU	$\beta_2$ -Microglobulin	N PROT STANDARD SL	6 1:20-	-1:640 urine	1:100 1:100	2 + 50 <b>N B2M REAGEN</b>	T 70 N SUPPLEMENT L	15 <b>N DILUENT</b>	55 <b>N DILUENT</b>	70	3 + 6
61	IgGC	lgG	N PROT STANDARD SL	6 1:80-1	:2 560 CSF	1:1 1:1	100 NAS IGG	40		100	60	6
62	IgAC	IgA		6 1:10-	-1:320 CSF serum	1:5 1:1 CSF 1:2 000 <sup>×</sup> 1:400 <sup>×</sup> serun	20 <b>[N IGA] [REAGEN</b> 1 20	50 NIGA SUPPLEMENT A + NIGA SUPPLEMENT	- 10	60 <b>N DILUENT</b>	60	6
63	IgMC	lgM		6 1:10-	-1:320 CSF	1:1 <sup>y</sup> 1:1	20 NIGM REAGEN	T 50 [N IGM] SUPPLEMENT / + [N IGM] SUPPLEMENT		60 N DILUENT	60	6
67	ALBC	Albumin	N PROT STANDARD SL	5 1:160-1	:2560 CSF	1:5 1:1	15 NAS ALB	30		100	130	6
	ens Assay No. natic dilution v	with Default Diluent (see	<ul> <li>Assay protocols are for in patient samples where</li> </ul>	or low protein concentrations hich require a lower		part of the Reagent Kit. lection of another sample dilution	<ul> <li>Serum sample dilution needs to be selected manually.</li> </ul>	y The "sample" dilution for <b>N CON LC2</b> is	5 1:5.			

System Manual).

measuring range. ich requir

her sample dilution manually. than 1:5 is not permissible.

# Addendum I Symbol Names of Required Materials, REF and SMN for all products

Symbol names are depicted onto the reagent labels and are not translatable. In the following table symbol names and corresponding product names in the language of these Assay Protocols are listed.

Symbol Name	Product Name	REF	SMN
APO CONTROL CHD	Apolipoprotein Control Serum CHD	OUPH09	10446469
CardioPhase <sup>®</sup> hsCRP	CardioPhase <sup>®</sup> hsCRP	OQIY13	10446090
		OQIY21	10446091
CardioPhase hsCRP <b>REAGENT</b>	<ul> <li>CardioPhase<sup>®</sup> hsCRP Reagent</li> </ul>		
Cleaner SCS	Cleaner SCS	OQUB21	10446436
N ADNS	N Latex ADNase B	OWTI15	10873691
N ADNS REAGENT	N ADNase B Reagent		
N ADNS STANDARD	<ul> <li>N ADNase B Standard Serum (human)</li> </ul>		
N ADNS CONTROL	<ul> <li>N ADNase B Control Serum (human)</li> </ul>		
N ADNS SUPPLEMENT	<ul> <li>N ADNase B Supplementary Reagent</li> </ul>		
N APO STANDARD	N Apolipoprotein Standard Serum	OUPG09	10446466
N AS A2M	N Antiserum to Human $\alpha_2$ Macroglobulin	OSAM21	10469773
N AS AAG	N Antiserum to Human $\alpha_1$ -acid Glycoprotein	OSAW15 OSAW09	10446307 10446306
N AS AAT	N Antiserum to Human $\alpha_1$ -Antitrypsin	OSAZ15 OSAZ09	10446312 10446311
N AS ALB	N Antiserum to Human Albumin	OSAL23 OSAL25	10714508 10714509
N AS APOAI	N Antiserum to Human Apolipoprotein A-I	OUED15 OUED09	10446438 10446437
N AS APOB	N Antiserum to Human Apolipoprotein B	OSAN15 OSAN09	10446287 10446286
N AS ATIII	N Antiserum to Human Antithrombin III	OSAY09	10446310
N AS C1IN	N Antiserum to Human C1-Inhibitor	OQEY09	10446049
N AS C3	N Antiserum to Human C3c	OSAP15 OSAP09	10446291 10446290
N AS C4	N Antiserum to Human C4	OSAO15 OSAO09	10446289 10446288
N AS CER	N Antiserum to Human Ceruloplasmin	OUIE09	10446451
N AS FIB	N Antiserum to Human Fibrinogen	OSCA09	10446313
N AS HAPT	N Antiserum to Human Haptoglobin	OSAV15 OSAV09	10446305 10446304
N AS HPX	N Antiserum to Human Hemopexin	OUVN09	10446493
N AS IGG1	N AS IgG1	OQXI09	10446168
N AS IGG2	N AS IgG2	OQXK09	10446169
N AS KAPPA	N Antiserum to Human Ig/L-chain, κ-type	OWHG13	10446595
	N Antiserum to Human Ig/L-chain, λ-type	OWHH13	10446597
NASL	N Latex ASL	OPBU03 OPBU05	10445983 10445984
N AS PLS	N Antiserum to Human Plasminogen	OSCB09	10446314
N AS PRE	N Antiserum to Human Prealbumin	OUIF09	10446452
N AS RBP	N Antiserum to Human RbP	OUVO09	10446494
N AS TRF	N Antiserum to Human Transferrin	OSAX15 OSAX09	10446309 10446308

I

Symbol Name	Product Name	REF	SMN
N B2M	N Latex β <sub>2</sub> -Microglobulin	OQWU21	10446162
N B2M REAGENT	<ul> <li>N Latex β<sub>2</sub>-Microglobulin Reagent</li> </ul>		
• N B2M U STAB	Urine Stabilizer		
N CDT	N Latex CDT Kit	OPCS05	10445997
N CDT REAGENT 1	• N CDT Reagent 1		
N CDT REAGENT 2	N CDT Reagent 2		
• N CDT SUPPLEMENT	<ul> <li>N CDT Supplementary Reagent</li> </ul>		
• N CDT STANDARD	N CDT Standard SL		
• N CDT CONTROL 1	N CDT Control SL/1		
• N CDT CONTROL 2	N CDT Control SL/2		
N CYSC	N Latex Cystatin C	OQNM19	10873631
N CYSC REAGENT	N Cystatin C Reagent		
• N CYSC CONTROL 1	N Cystatin C Control Level 1		
N CYSC CONTROL 2	N Cystatin C Control Level 2		
N CYSC SUPPLEMENT A	• N Cystatin C Supplementary Reagent A		
N CYSC SUPPLEMENT B	• N Cystatin C Supplementary Reagent B		
	N Diluent	OUMT65	10446457
N FLC CONTROL SL1	N FLC Control SL1	OPJE05	10873661
N FLC CONTROL SL2	N FLC Control SL2	OPJF05	10873663
N FLC STANDARD SL	N FLC Standard SL	OPJD05	10873662
	N FLC Supplementary Reagent	OPJC05	10873660
• N FLC SUPPLEMENT A	N FLC Supplementary Reagent A		
N FLC SUPPLEMENT B	N FLC Supplementary Reagent B		
N FLC KAPPA	N Latex FLC kappa	OPJA07	10873629
	N Latex FLC lambda	OPJB07	10873630
N FRT	N Latex Ferritin	OQTH11	10446130
• N FRT REAGENT	N Latex Ferritin Reagent		
• N FRT SUPPLEMENT A	N Ferritin Supplementary Reagent A		
• N FRT SUPPLEMENT B	N Ferritin Supplementary Reagent B		
	N Latex HCY	OPAX03	10445973
	N HCY Reagent		
• NHCY RA	• N HCY RA		
• NHCY SR A	• N HCY SR A		
• NHCY SR B	• N HCY SR B		
N IGA	N Latex IgA	OQAI15	10873689
	N IgA Reagent		
N IGA STANDARD	• N IgA Standard (human)		
• NIGA CONTROL	• N IgA Control (human)		
	• N IgA Supplementary Reagent A		
N IGA SUPPLEMENT B	• N IgA Supplementary Reagent B		
N IGE	N Latex IgE mono	OQTG15	10446129
N IGG3	N Latex IgG3	OPAV03	10445972
N IGG3 REAGENT	• N Latex IgG3	0	
N IGG4	N Latex IgG4	OPAU03	10445971
NIGG4 REAGENT	• N Latex IgG4	017005	10113771
	- N Latex 1907		

Symbol Name	Product Name	REF	SMN
N IGM	N Latex IgM	OQAC15	10873688
• NIGM REAGENT	• N lgM Reagent		
• NIGM STANDARD	<ul> <li>N IgM Standard (human)</li> </ul>		
• NIGM CONTROL	N IgM Control (human)		
• NIGM SUPPLEMENT A	N IgM Supplementary Reagent A		
• NIGM SUPPLEMENT B	<ul> <li>N IgM Supplementary Reagent B</li> </ul>		
N LP(A) REAGENT	N Latex Lp(a) Reagent	OQHL11	10446069
N LP(A) CONTROL SY	N Lp(a) Control SY	OQCW07	10873687
N LP(A) STANDARD SY	N Lp(a) Standard SY	OQCV07	10873686
N MYO	N Latex Myoglobin	OWIA17	10873690
• N MYO REAGENT	• N Myoglobin Reagent		
• N MYO STANDARD	<ul> <li>N Myoglobin Standard (human)</li> </ul>		
• N MYO CONTROL	<ul> <li>N Myoglobin Control (human)</li> </ul>		
• N MYO SUPPLEMENT A	N Myoglobin Supplementary Reagent A		
• N MYO SUPPLEMENT B	N Myoglobin Supplementary Reagent B		
N PROT STANDARD PY	N Protein Standard PY	OUID15	10446450
N PROT STANDARD SL	N Protein Standard SL	OQIM19	10873692
N PROT STANDARD UY	N Protein Standard UY	OQLV11	10873632
NRF	N Latex RF Kit	OPCE03	10445991
		OPCE05	10445992
• N RF REAGENT	• N RF Reagent		
• N RF SUPPLEMENT	N RF Supplement		
N RHEUMA STANDARD SL	N Rheumatology Standard SL	OQKZ15	10873683
N STFR	N Latex sTfR	OQTC11	10446127
	N Supplementary Reagent L	OQTD11	10446128
N SUPPLEMENT L/A	<ul> <li>N Supplementary Reagent L/A</li> </ul>		
• N SUPPLEMENT L/B	<ul> <li>N Supplementary Reagent L/B</li> </ul>		
N/T PROT CONTROL LC	N/T Protein Control LC	OQLW15	10446105
N/T PROT CONTROL PY	N/T Protein Control PY	OWSY15	10446656
N/T PROT CONTROL SL/H	N/T Protein Control SL/H	OQIP19	10446089
N/T PROT CONTROL SL/L	N/T Protein Control SL/L	OQIN19	10446079
N/T PROT CONTROL SL/M	N/T Protein Control SL/M	0QI019	10446085
N/T RHEUMA CONTROL SL/1	N/T Rheumatology Control SL/1	OQDB17	10873684
N/T RHEUMA CONTROL SL/2	N/T Rheumatology Control SL/2	OQDC17	10873685
N A1M	N α <sub>1</sub> -Microglobulin Kit	OWLA11	10446619
• NASA1M	<ul> <li>N Antiserum to Human α<sub>1</sub>-Microglobulin</li> </ul>		
	<ul> <li>N Supplementary Reagent A</li> </ul>		
NASIGA	N Antiserum to Human IgA	OSAR19 OSAR11	10446295 10446293
NASIGG	N Antiserum to Human IgG	OSAS19 OSAS11	10446299 10446297
NASIGM	N Antiserum to Human IgM	OSAT19 OSAT11	10446303 10446301
	N Supplementary Reagent/Precipitation	OUMU15	10446458

**Siemens Healthineers Headquarters** Siemens Healthcare GmbH Henkestraße 127 91052 Erlangen/Germany Phone: +49 9131 84-0 siemens-healthineers.com



Siemens Healthcare Diagnostics Products GmbH Emil-von-Behring-Str. 76 35041 Marburg/Germany

**RxOnly** 

© Siemens Healthineers, 2019–2022. All rights reserved.

siemens-healtineers.com



## N Antiserum to Human IgG

NAS IGG

## N Antiserum to Human IgA

NAS IGA

## N Antiserum to Human IgM

NAS IGM

Revision bar indicates update to previous version.

BN II / BN ProSpec® System

### **Intended Use**

*In-vitro* diagnostic reagents for the quantitative determination of immunoglobulins (IgG, IgA and IgM) in human serum, heparinized and EDTA plasma, and IgG in human urine and cerebrospinal fluid (CSF) by means of immunonephelometry on the BN II and BN ProSpec<sup>®</sup> System. Measurements of IgG aid in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agents.

## **Summary and Explanation**

Immunoglobulins are formed by plasma cells as a humoral immune response to contact of the immune system with antigens. The primary reaction after the initial contact is the formation of antibodies of the IgM class followed later by IgG and also IgA antibodies. Quantitative determination of the immunoglobulins can provide important information on the humoral immune status<sup>1</sup>. Decreased serum immunoglobulin concentrations occur in primary immunodeficiency conditions as well as in secondary immune insufficiencies, e.g., in advanced malignant tumours, lymphatic leukemia, multiple myeloma and Waldenstrom's disease. Increased serum immunoglobulin concentrations occur due to polyclonal or oligoclonal Ig proliferation, e.g., in hepatic diseases (hepatitis and liver cirrhosis), acute and chronic infections, autoimmune diseases as well as in the cord blood of neonates with intra-uterine and perinatal infections<sup>2</sup>. Monoclonal immunoglobulin proliferations are observed e.g. in plasmacytomas, Waldenstrom's disease and heavy-chain disease<sup>2</sup>. Monoclonal immunoglobulinemia requires detailed differential diagnostic investigations in addition to the quantitative determination. Local immune reactions with the centralnervous system result in elevated immunoglobulin levels, particularly IgG, in the cerebrospinal fluid<sup>3</sup>.

Elevated urinary concentrations of IgG are found in patients with non-selective glomerular proteinuria<sup>4</sup>.

## **Principles of the Method**

Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity

of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

## Reagents

#### Materials provided

NASIGG, REF OSAS

1 x 5 mL NASIGG, N Antiserum to Human IgG (γ chain) or

1 x 2 mL NASIGG, N Antiserum to Human IgG (γ chain) or

NASIGA, REF OSAR

1 x 5 mL [N AS] IGA, N Antiserum to Human IgA ( $\alpha$  chain) or

1 x 2 mL NASIGA, N Antiserum to Human IgA ( $\alpha$  chain) or

NASIGM, REF OSAT

1 x 5 mL  $\hbox{${\rm NAS}$ IGM]},$  N Antiserum to Human IgM ( $\mu$  chain) or

1 x 2 mL NASIGM, N Antiserum to Human IgM (µ chain)

#### Composition

N Antisera are liquid animal sera and are produced by immunization of rabbits with highly purified human immunoglobulin (IgG, IgA or IgM). The concentration of active antibodies is < 3.5 g/L to human IgG, < 4.3 g/L to human IgA and < 32.9 g/L to human IgM.

Preservative

N Antiserum to Human IgG, IgA or IgM: sodium azide < 1 g/L

#### **Warnings and Precautions**

For *in-vitro* diagnostic use only.

For laboratory professional use.

Safety data sheets (MSDS/SDS) available on siemens-healthineers.com/sds.

#### CAUTION!

Federal (USA) law restricts this device to sale by or on the order of licensed healthcare professionals.

#### Caution

#### NAS IGG, NAS IGA, NAS IGM

This device contains material of animal origin and should be handled as a potential carrier and transmitter of disease.

Contains sodium azide as a preservative. Sodium azide can react with copper or lead plumbing to form explosive metal azides. On disposal, flush reagents with a large volume of water to prevent the buildup of azides. Disposal into drain systems must be in compliance with prevailing regulatory requirements.

Dispose of hazardous or biologically contaminated materials according to the practices of your institution. Discard all materials in a safe and acceptable manner and in compliance with all government requirements.

#### Preparation of Reagents

The N Antisera are ready-for-use as supplied and require no additional preparation.

#### **Storage and Stability**

Stability at 2 to 8 °C:

see expiry date on label;

#### Stability once opened:

four weeks if stored at 2 to 8 °C securely capped immediately after each use and if contamination (e.g., by microorganisms) is precluded;

During storage, N Antisera can develop precipitates or turbidity which are not caused by microbial contamination and which do not affect their activity. In such cases, the antiserum should be filtered prior to use. Disposable filters with a pore size of 0.45  $\mu$ m are suitable for this purpose.

#### Do not freeze.

On-board stability:

a minimum of five days at eight hours per day or a comparable period of time.

Note: on-board stability may vary, depending on BN System used and laboratory conditions. For further details, refer to BN II or BN ProSpec® System Instruction Manual.

#### Materials required but not provided

BN II or BN ProSpec® System N Protein Standard SL, REF OQIM N/T Protein Control SL/L, M and H, REF OQIN, OQIO and OQIP N/T Protein Control LC, REF OQLW N Reaction Buffer, REF OUMS N Diluent, REF OUMT N Supplementary Reagent/Precipitation, REF OUMU (for use with the low-concentration IgA and IgM assay protocols) BN II Evaporation Stoppers (optional), REF OVLE Additional materials and supplies as described in your BN System Instruction Manual.

### Specimens

Suitable samples are human serum, heparinized or EDTA plasma, either as fresh as possible (stored no more than eight days at 2 to 8 °C) or stored frozen. Fresh human urine stored for no more than three days at 2 to 8 °C and fresh CSF samples stored for no more than seven days at 2 to 8 °C are also suitable for the IgG determination. If paired serum and CSF samples are to be analyzed, they should be drawn simultaneously.

Serum and plasma samples can be stored at below -20 °C for up to three months if they are frozen within 24 hours after collection and if repeated freeze-thaw cycles are avoided. Serum samples must be completely coagulated and, after centrifugation, must not contain any particles or traces of fibrin. Lipemic samples or frozen samples which became turbid after thawing must be clarified by centrifugation (10 minutes at approximately 15,000 x g) prior to testing. Random and timed urine collections are suitable specimens for testing IgG in urine. Urine and CSF samples which have been stored frozen must not be used. Each urine and CSF sample must be centrifuged prior to testing.

### Procedure

#### Notes

1. Consult your BN System Instruction Manual for details regarding operation of the instrument.

2. Reagents and samples stored at 2 to 8 °C can be used immediately.

#### Assay Protocols for BN Systems

The assay protocols for serum and plasma, as well as for IgG in urine and CSF, respectively, are given in the BN System Instruction Manual and software of the instrument. All steps are performed automatically by the system.

#### **Establishment of the Reference Curve**

Reference curves are generated by multi-point calibration. Serial dilutions of N Protein Standard SL are automatically prepared by the instrument using N Diluent. The standard dilutions are to be used within four hours.

The reference curves can be used for as long as controls with corresponding method-dependent target values, e.g. N/T Protein Control SL/L, M and H for the serum/plasma assay and N/T Protein Control LC for the IgG in urine and CSF assay, are reproduced within their respective range. If a different lot of antiserum is used, a new reference curve must be generated.

#### **Assay of Specimens**

Serum and plasma samples are automatically diluted 1:400 (IgG), 1:20 (IgA, IgM) or 1:5 in the lowconcentration assay protocols (IgAs and IgMs) with N Diluent. The diluted samples must be measured within four hours. IgG in urine or CSF is measured from undiluted samples using a separate assay protocol. IgG in serum and CSF can also be analyzed using a single reference curve, provided that the appropriate sample dilution is selected manually.

If the results obtained are outside the measuring range, the assay can be repeated using a higher or lower dilution of the sample (IgG in the serum/plasma assay protocol). Urine sample results that are outside the intial measuring range can be repeated using a higher dilution of the sample. Refer to BN System's Instruction Manual for information on repeat measurements using other dilutions.

If the reading in the regular IgA or IgM assay protocol (1:20 sample dilution) is below the measuring range, the sample may be re-tested from the respective low-concentration assay protocol by a new request.

#### **Internal Quality Control**

Assay N/T Protein Controls SL/L, M and H after each establishment of a reference curve, the first use of an antiserum vial as well as with each run of serum or plasma samples. For the determination of IgG in urine or CSF samples the N/T Protein Control LC should be used accordingly. The controls are assayed and evaluated as for patient samples. The assigned value and range are listed in the Table of Assigned Values of the respective control.

Follow government regulations or accreditation requirements for quality control frequency.

If the result of a control is outside the range, the determination must be repeated. If the repeated determination confirms the deviation, a new reference curve should be established. Do not release patient results until the cause of deviation has been identified and corrected.

### Results

Evaluation is performed automatically in g/L or in a derived unit selected by the user on the BN System.

## Limitations of the Procedure

Turbidity and particles in the sample may interfere with the determination. Therefore, samples containing particles must be centrifuged prior to testing. Lipemic or turbid samples which cannot be clarified by centrifugation (10 minutes at approximately 15,000 x g) must not be used. The immunoglobulin assays have been designed to minimize antigen excess in the initial sample dilutions. However, it cannot be completely eliminated and in rare cases very high immunoglobulin may show reactivity different from the polyclonal standard, which in isolated cases may lead to artificially decreased or non-linear results. In case of serum or plasma determinations, the constellation of IgG, IgA and IgM should be assessed. A check of IgG results in CSF should be performed by means of ratio diagrams<sup>3</sup>. In case of questionable results, the determinations should be repeated using the next higher sample dilution. For patient monitoring, consecutive immunoglobulin determinations should be performed from the same sample dilution, as far as possible.

Siemens Healthineers has validated use of these reagents on various analyzers to optimize product performance and meet product specifications. User defined modifications are not supported by Siemens Healthineers as they may affect performance of the system and assay results. It is the responsibility of the user to validate modifications to these instructions or use of the reagents on analyzers other than those included in Siemens Healthineers Reference Guides (Application Sheets) or these Instructions for Use.

Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

Due to matrix effects, inter-laboratory survey samples and control samples may yield results that differ from those obtained with other methods. It may therefore be necessary to assess these results in relation to method-specific target values.

### **Reference Intervals**

The following reference intervals apply for serum and plasma samples from healthy adults<sup>5</sup>: **Protein** 

lgG	7.0	-	16.0	g/L
lgA	0.7	-	4.0	g/L
lgM	0.4	-	2.3	g/L

During childhood and adolescence reference ranges for IgG, IgA, IgM are dependent on age and can vary over a wide range<sup>6</sup>:

.ge					
	males		females		
age (years)	2.5 <sup>th</sup> percentile (g/L)	97.5 <sup>th</sup> percentile (g/L)	2.5 <sup>th</sup> percentile (g/L)	97.5 <sup>th</sup> percentile (g/L)	
1	3.5	8.6	4.0	9.8	
4	5.1	12.6	5.3	13.0	
7	6.0	14.7	5.9	14.6	
10	6.6	16.2	6.4	15.9	
14	6.6	16.2	6.8	16.7	
18	6.5	16.0	6.9	17.0	

lgA

laG

	males		females	
age (years)	2.5 <sup>th</sup> percentile (g/L)	97.5 <sup>th</sup> percentile (g/L)	2.5 <sup>th</sup> percentile (g/L)	97.5 <sup>th</sup> percentile (g/L)
1	0.17	0.96	0.17	0.94
4	0.36	1.98	0.33	1.85
7	0.48	2.66	0.44	2.44
10	0.57	3.18	0.52	2.90
14	0.64	3.52	0.62	3.43
18	0.68	3.79	0.69	3.80

lgΜ

	ma	males		ales
age (years)	2.5 <sup>th</sup> percentile (g/L)	97.5 <sup>th</sup> percentile (g/L)	2.5 <sup>th</sup> percentile (g/L)	97.5 <sup>th</sup> percentile (g/L)
1	0.30	1.83	0.34	2.06
4	0.35	2.13	0.42	2.55
7	0.37	2.26	0.45	2.78
10	0.38	2.35	0.48	2.94
14	0.40	2.44	0.50	3.09
18	0.41	2.51	0.52	3.22

*Reference interval for IgG in urine samples:* 

IgG in second morning urine below 9.6 mg/L<sup>4</sup>.

Note: Value adapted to IFCC/BCR/CAP reference preparation ERM-DA470 by applying a conversion factor of 0.85.

Reference interval for IgG in CSF samples:

IgG in CSF: below 34 mg/L<sup>3</sup>

Note: Value adapted to IFCC/BCR/CAP reference preparation ERM-DA470 by applying a conversion factor of 0.85.

Reference intervals in the strict sense exist only for CSF/serum ratios<sup>3</sup>.

Nevertheless, each facility should determine its own reference intervals since values may vary depending on the individual population studied.

## **Specific Performance Characteristics**

#### Assay Range

The N Antisera to Human IgG, IgA and IgM are designed to measure immunoglobulin concentrations within a range of approximately:

lgG	1.4	-	46	g/L
lgA	0.25	-	8.0	g/L
lgAs	0.06	-	2.0	g/L
lgM	0.2	-	6.4	g/L
lgMs	0.05	-	1.6	g/L

for a sample dilution of 1:400 (IgG), 1:20 (IgA, IgM) and 1:5 (IgAs, IgMs) in serum or plasma. The N Antiserum to Human IgG is designed to measure IgG concentrations within a range of approximately 3.6 to 58 mg/L for neat urine samples and 3.6 to 115 mg/L for neat CSF samples.

#### The Limit of Quantitation

The Limit of Quantitation (LoQ) is determined consistent with CLSI/NCCLS Guideline EP17-A and the allowable total error of 30 %. LoQ is the lowest amount of analyte that can be quantitatively determined within a defined total error.

IgG - Serum/Plasma	0.07 g/L
lgG - CSF	3.6 mg/L
lgG - Urine	3.6 mg/L
IgA - Serum/Plasma	0.25 g/L
IgM - Serum/Plasma	0.20 g/L

#### Specificity

The specificity of N Antiserum to Human IgG, IgA and IgM, respectivly, is tested against human serum and plasma pools and preparations of human IgG, IgA, IgM and Bence-Jones proteins, type Kappa and Lambda in different analytical methods. There are no known cross-reactivities of the antisera used.

No interference with the determinations in serum was detected for concentrations of triglycerides up to 19 g/L (IgG), 5.7 g/L (IgA), 9.9 g/L (IgA low-concentration protocol) and 4.6 g/L (IgM low concentration protocol), bilirubin at 600 mg/L, and free hemoglobin at 10 g/L. No interference from commonly drugs is known.

No interference with the determinations of IgG in urine was detected for concentrations of bilirubin up to 3 mg/dL, and free hemoglobin up to 10 g/L.

#### Non Interfering Substances

The following substances do not interfere with the IgG assay when present in urine at the concentrations indicated. Inaccuracies (biases) due to these substances are less than 10 % at the urine concentrations listed.

Substance	Substance Test Concentration mg/dL	lgG Concentration mg/L
Acetone	1000	7.70
Ascorbic acid	900	20.9
Ethanol	1000	7.70
Oxalic acid	10	24.9
Riboflavin	6.75	28.5
Sodium chloride	6000	7.37

Substance	Substance Test Concentration mg/dL	IgG Concentration mg/L		
Bovine albumin	500	23.6		
Boric acid	4500	21.6		
Sodium azide	20000	23.6		
Sodium fluoride	16000	21.4		
Hook Effect: The IgG urine assay shows no hook effect up to 998 mg/L.				

#### Precision

The following coefficients of variation (CV) were obtained with N Antisera to Human Immunoglobulins (n=40) on a BN System:

lgG / Serum	mean (g/L)	Run-to-Run CV (%)	Within-Run CV (%)	Total CV (%)
N/T Protein Control, SL/L	5.0	2.1	3.0	3.4
N/T Protein Control, SL/M	8.4	1.4	1.8	2.1
N/T Protein Control, SL/H	12.1	1.5	2.6	2.7
Serum Pool (low)	8.8	1.7	1.8	2.3
Serum Pool (high)	12.7	1.5	2.2	2.4
lgG / CSF	mean (mg/L)	Run-to-Run CV (%)	Within-Run CV (%)	Total CV (%)
N/T Protein Control LC	18.7	0.7	1.2	1.3
CSF pool (low)	8.1	0.8	1.3	1.4
CSF pool (high)	42.1	1.0	1.8	1.9
lgG / Urine	mean (mg/L)	Run-to-Run CV (%)	Within-Run CV (%)	Total CV (%)
N/T Protein Control LC	18.8	0.8	1.1	1.3
Urine pool (low)	5.5	3.2	2.9	4.1
Urine pool (high)	19.9	2.5	1.2	2.8
lgA / Serum	mean (g/L)	Run-to-Run CV (%)	Within-Run CV (%)	Total CV (%)
N/T Protein Control, SL/L	1.0	3.7	1.6	4.1
N/T Protein Control, SL/M	1.7	2.7	3.3	4.0
N/T Protein Control, SL/H	2.5	2.1	2.5	3.1
Serum Pool (low)	2.0	2.1	3.2	3.5
Serum Pool (high)	2.5	2.3	2.6	3.3
lgM / Serum	mean (g/L)	Run-to-Run CV (%)	Within-Run CV (%)	Total CV (%)
N/T Protein Control, SL/L	0.47	4.0	3.8	5.3
N/T Protein Control, SL/M	0.69	1.9	3.2	3.4

lgM / Serum	mean (g/L)	Run-to-Run CV (%)	Within-Run CV (%)	Total CV (%)
N/T Protein Control, SL/H	0.90	1.7	2.6	2.8
Serum Pool (low)	0.76	1.9	2.2	2.7
Serum Pool (high)	1.12	1.7	1.7	2.2

The study was performed consistent with CLSI guideline EP5-A on ten days with four replicates per day (n = 40).

The results were generated by analysis of variance.

#### **Method Comparison**

One hundred (100) serum samples were assayed with N Antisera to Human Immunoglobulins on a BN System (y) and a radial immunodiffusion (RID) method (x). Correlation of the results yielded the following data:

Protein		Coefficient of Correlation
IgG	y (BN) = 1.09 x (RID) - 0.12 g/L	0.97
IgA	y (BN) = 0.99 x (RID) + 0.06 g/L	0.99
lgM	y (BN) = 1.08 x (RID) - 0.06 g/L	0.99

Seventy-six human urine samples ranging from 3.7 mg/L to 52 mg/L were assayed with N Antisera to Human Immunoglobulins (IgG) on a BN ProSpec<sup>®</sup> System and on a commercially available immunochemistry system. The method used to fit the linear regression line was Passing Bablok.

Protein		Coefficient of Correlation
lgG	y = 0.926 x - 0.34 mg/L	0.99

#### Note

The values cited for specific performance characteristics represent typical values and are not to be regarded as specifications for the N Antisera to Human IgG, IgA and IgM.

### **Technical Assistance**

For customer support, contact your local technical support provider or distributor. siemens-healthineers.com

#### **Current Version of Assay Protocols**

**NAS** IGA, **NAS** IGG and **NAS** IGM can be used in combination with various automated analyzers. Siemens Healthineers provides Assay protocols for instruments under the dedicated link below: siemens-healthineers.com/ap

As Siemens Healthineers continuously monitors the product performance and safety, the users are required to ensure that they work with the correct revision of the instructions for the product lots in use. Please periodically review the availability of new electronic labeling revisions to ensure safe use of the product.

The IFU version number is visible on each product box label. Siemens Healthineers ensures that all products lots bearing the same IFU version number are compatible with the electronic labeling provided via siemens-healthineers.com/eIFU.

### Bibliography

- 1. Thomas L. Immunoglobulins (Ig). In: Thomas L (ed.) Clinical Laboratory Diagnostics, Frankfurt/ Main: TH-Books Verlagsgesellschaft, 1998: 667-78.
- 2. Attaelmannan M, Levinson SS. Understanding and identifying monoclonal gammopathies. Clin Chem 2000;46:1230-8.
- 3. Reiber, H., Aktuelle Methoden der Liquoranalytik. Labmed 1998; 12:101-9).

- 4. Hofmann W, Guder WG. A diagnostic programme for quantitative analysis of proteinuria. J Clin Chem Clin Biochem 1989;-27:-589-600.
- 5. Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem 1996; 34: 517-20.
- 6. Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal. 1998; 12: 363-70.

## **Definition of Symbols**

The following symbols may appear on the product labeling:

(	Do not reuse	22	Use By
LOT	Batch Code	REF	Catalogue Number
$\triangle$	Caution		Manufacturer
EC REP	Authorized representative in the European Community	Σ	Contains sufficient for <n> tests</n>
Ś	Biological Risks	IVD	<i>In Vitro</i> Diagnostic Medical Device
	Temperature Limitation		Consult instruction for Use
NON STERILE	Non-sterile	CE	CE marking of conformity
C€0197	CE marking of conformity with notified body ID number. Notified body ID number can vary.	CONTENTS	Contents
$\rightarrow$	Reconstitution volume	LEVEL	Level
×	Keep away from sunlight and heat	WARNING	Warning
DANGER	Danger	RxOnly	Prescription device (US only)
UDI	Device Identification (UDI) barcode	<b>REACH</b> xx/xx/xx	REACH Authorization Number

## **Legal Information**

BN ProSpec is a trademark of Siemens Healthineers. All other trademarks are the property of their respective owners.

© Siemens Healthineers, 2010–2021. All rights reserved.

#### **Siemens Healthineers Headquarters**

Siemens Healthcare GmbH Henkestraße 127 91052 Erlangen Germany Phone: +49 9131 84-0 siemens-healthineers.com

#### •••

Siemens Healthcare Diagnostics Products GmbH Emil-von-Behring-Str. 76 35041 Marburg Germany siemens-healthineers.com

## BN™II Online Refresher

- 1. The BN<sup>™</sup>II uses what method of measurement?
  - a. Turbidity
  - b. Chromogenic
  - c. Nephelometry
  - d. Immunoassay
- 2. How do you enter the lot data for standards and controls?
  - a. Load the lot data USB
  - b. Scan the barcodes on the package insert sheets
  - c. Download the lot data from Siemens Document Library
  - d. Copy and paste the lot data file
- 3. How can you trigger the emergency stop on the BN™II?
  - a. Lift the front panel / Plexiglas
  - b. Click System, Emergency stop
  - c. Open the left panel door
  - d. Press the toggle switch on the left side of the analyzer
- 4. What is the name of the dialog where patient results can be reviewed?
  - a. Work list
  - b. Lab journal
  - c. Job list
  - d. Sample list
- 5. What is used to dilute the samples?
  - a. Buffer
  - b. BN™II Additive
  - c. Diluent
  - d. Wash solution
- 6. Samples are diluted with diluent in the
  - a. Wash station
  - b. Dilution cups
  - c. Cuvettes
  - d. Sample cups

- 7. What is loaded in the first five rack lanes?
  - a. Patient samples
  - b. Controls
  - c. Reagents
  - d. Standards
- 8. Which of these is not a function of the probes?
  - a. Pipetting
  - b. Mixing
  - c. Heating
  - d. Cap piercing
- 9. You may pool liquids on the BN<sup>™</sup>II as long as they have the same lot number.
  - a. True
  - b. False
- 10. Level sensor s monitor the liquid level in the system liquid and waste containers.
  - a. True
  - b. False
- 11. Samples with low volume should be run in .....
  - a. A cup placed in the sample tube
  - b. A cup placed in a sample rack
  - c. A micro centrifuge tube placed in a pediatric rack
  - d. None of the above
- 12. After initialization of the BN<sup>™</sup>II is completed, what needs to be done prior to running samples?
  - a. Update the number of usable cuvettes
  - b. Empty the waste container
  - c. Update the number of clean dilution wells
  - d. All of the above

## Day 2 Eye Opener

- 1. What lanes should the supplemental reagents be loaded?
  - a. Lane 1 or 2 in the rack for 2 ml vials b.
  - Lanes 3 5 in the rack for 2 ml vials
  - c. Lanes 1 or 2 in the rack for 5 ml vials
  - d. Lanes 3 5 in the rack for 5 ml vials
- 2. How long are the reference curves valid?
  - a. As long as the controls are valid
  - b. 7 days
  - c. 1 month
  - d. 3 months
- 3. Which of the following can prevent initialization of the system?
  - a. No dilution strips in the dilution frames
  - b. Dilution frames not seated properly
  - c. Full waste container
  - d. Empty buffer container
- 4. What does it mean if an **H** is displayed next to the result in the Lab journal?
  - a. Value is outside of measuring range and must be diluted
  - b. Result has been sent to the host
  - c. Result is outside if the reference (normal) range
  - d. Result is a panic and should be repeated
- 5. Which options would you use to order controls?
  - a. Routine > Request controls
  - b. Control journal > Request controls
  - c. QC > Request controls
  - d. Reference curves > Request controls
- 6. What is the acceptable mean deviation for most calibrations?
  - a. < 5%
  - b. < 7%
  - c. ± 15%
  - d. ±20%

7. How many reagent lot numbers can be calibrated for non-kit assays?

- a. 1
- b. 2
- c. 3
- d. 4
- 8. How many reagent lots can be calibrated for a kit assay?
  - a. 1
  - b. 2
  - c. 3
  - d. 4
- 9. Which option would you choose to see the contents of each rack?
  - a. Lab journal
  - b. Rack status
  - c. Loading
  - d. Configuration
- 10. How do you eject a USB / memory stick from the Macintosh?
  - a. Click System, Eject disk
  - b. Click, hold and drag the disk icon to the trash
  - c. Click Start, Eject disk
  - d. At the bottom right of the screen, click the USB icon and "Safely Remove Hardware and Eject Media"

## Finale

- 1. There is an X flag next to an IgG result in the Lab Journal. What will resolve this?
  - a. No resolution needed. Report the result.
  - b. Spin the sample at the recommended speed and time, then rerun.
  - c. Report as "unable to report due to specimen condition"
  - d. Freeze the sample and rerun the next day
- 2. Your initial IgG results and repeats are out of range for the low, medium and high controls. What would you do?
  - a. Open new controls
  - b. Recalibrate IgG after troubleshooting
  - c. Clean the probe
  - d. Request another repeat
- 3. On the Reagent List what does a black **x** mean?
  - a. Reagent is not loaded in Lanes 3-5
  - b. Reagent should be loaded in Lanes 3-5
  - c. Reagent is empty
  - d. Reagent is no longer needed
- 4. How often should you perform purging?
  - a. Weekly
  - b. Monthly
  - c. Semi-annually
  - d. Yearly
- 5. What are the components of the Wash solution?
  - a. Distilled water and neodisher
  - b. Distilled water and BN™II Additive
  - c. Distilled water and 70% Ethanol
  - d. Distilled

- 6. In the Lab Journal, what is the reason for the blue x?
  - a. No active reference curve exists
  - b. Valid reference curve exists
  - c. Active reference curve exists
  - d. Invalid curve
- 7. Which folder contains calibration curves and assigned values for standards and controls?
  - a. BN II folder
  - b. Macintosh folder
  - c. System folder
  - d. Data folder
- 8. When is the wash filter changed?
  - a. Weekly
  - b. Monthly after Purging, before changing the cuvettes
  - c. Monthly after changing the cuvettes
  - d. Semi-annually
- 9. When running samples in the pediatric rack, choose Loading and which option after selecting the rack number:
  - a. Autoload
  - b. Autoload > Take
  - c. Autoload > Ignore all empty positions
  - d. Click each sample in the work list to load
- 10. The system performs a turbidity check on:
  - a. All samples
  - b. All assays using clear antisera
  - c. All latex assays
  - d. All non-kit assays

From (Date):           Daily maintenance         1         2         3           The system liquid containers         have been checked for sufficient contents         1         2         3																										
ontainers 1 2											-	lo (Date):	:(ə													
The system liquid containers have been checked for sufficient contents	4 5	5 6	2	∞	6	10	1	12	13 1	14	15 1	15 16	5 17	18	19	20	21	22	23	24	26	27	28	29	30	31
The dilution frames have been checked for presence, correct positioning, and completeness of the dilution wells																										
The analyzer's right cover has been closed																										
The tubing has been checked for kinks, contamination, leakage, and air bubbles																										
The external waste container has been emptied																										
The preparatory measures for analysis according to (+ Page 149 <i>Preparing for the</i> <i>analysis</i> ) have been performed																										
Signature / Initials:																										

Ana	alyzer ID:					
We	ekly maintenance	Week 1	Week 2	Week 3	Week 4	Week 5
1.	The surface of the analyzer, the rotor cover, the trough for the dilu- tion frames and the rack lanes have been cleaned					
2.	The syringes and valves have been checked for leakage					
3.	The reagent and sample probes have been checked for damage or blockage					
4.	The reagent and sample probes have been cleaned					
Ren	nark:					
Dat	e:					
Sig	nature:					

### 10.8.2 Weekly maintenance

### 10.8.3 Monthly maintenance

Ana	lyzer ID:	
Мо	nthly maintenance	
1.	The system tubing has been purged	
2.	The cuvettes have been replaced	
3.	The level sensors have been cleaned	
4.	The washing solution containers have been replaced	
5.	The washing solution filters have been replaced	
6.	The mouse has been cleaned	
Ren	nark:	
Dat	9:	
Sig	nature:	

## 10.8.4 Half-yearly maintenance

Ana	lyzer ID:	
Hal	f-yearly maintenance	
1.	The syringes have been maintained with silicon oil	
2.	The syringes with white piston heads have been replaced	
Ren	nark:	
Date	9:	
Sig	nature:	

### 10.8.5 Yearly maintenance

Ana	alyzer ID:	
Yea	rly maintenance	
1.	The syringes with black piston heads have been replaced	
Ren	nark:	
Dat	e:	
Sig	nature:	